iCAD (ICAD) 10-K 30 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 26, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	ICAD
Entity Registrant Name	ICAD INC
Entity Central Index Key	749,660
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		16,603,474
Entity Public Float			$ 58,099,626

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 9,387	$ 8,585
Trade accounts receivable, net of allowance for doubtful accounts of $107 in 2017 and $172 in 2016	8,599	5,189
Inventory, net	2,123	3,727
Prepaid expenses and other current assets	1,100	1,128
Assets held for sale		1,304
Total current assets	21,209	19,933
Property and equipment:
Equipment	5,722	7,180
Leasehold improvements	62	62
Furniture and fixtures	305	305
Marketing assets	376	376
Total property and equipment	6,465	7,923
Less accumulated depreciation and amortization	5,889	6,538
Net property and equipment	576	1,385
Other assets:
Other assets	53	53
Intangible assets, net of accumulated amortization of $7,433 in 2017 and $7,518 in 2016	1,931	3,183
Goodwill	8,362	14,097
Total other assets	10,346	17,333
Total assets	32,131	38,651
Current liabilities:
Accounts payable	1,362	1,577
Accrued expenses	4,475	4,988
Notes payable-current portion	817
Capital lease payable, short-term portion	12	86
Deferred revenue	5,404	5,372
Liabilities held for sale		832
Total current liabilities	12,070	12,855
Other long-term liabilities	119	83
Deferred revenue, long-term portion	506	668
Notes payable, long-term portion	5,119
Capital lease-long-term portion	27
Deferred tax	14	7
Total liabilities	17,855	13,613
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.
Common stock, $ .01 par value: authorized 30,000,000 shares; issued 16,711,752 in 2017 and 16,260,663 in 2016; outstanding 16,525,681 in 2017 and 16,074,832 in 2016	167	163
Additional paid-in capital	217,389	213,899
Accumulated deficit	(201,865)	(187,609)
Treasury stock at cost, 185,831 shares in 2017 and 2016	(1,415)	(1,415)
Total stockholders' equity	14,276	25,038
Total liabilities and stockholders' equity	$ 32,131	$ 38,651

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 107	$ 172
Intangible assets, accumulated amortization	$ 7,433	$ 7,518
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	16,711,752	16,260,663
Common stock, shares outstanding	16,525,681	16,074,832
Treasury stock, shares	185,831	185,831

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Products	$ 13,554	$ 10,471	$ 14,198
Service and supplies	14,548	15,867	27,356
Total revenue	28,102	26,338	41,554
Cost of Revenue:
Products	2,660	918	3,130
Service and supplies	6,229	5,713	7,357
Amortization and depreciation	1,037	1,189	1,717
Total cost of revenue	9,926	7,820	12,204
Gross profit	18,176	18,518	29,350
Operating expenses:
Engineering and product development	9,327	9,518	9,163
Marketing and sales	10,503	10,179	12,404
General and administrative	7,877	7,675	8,788
Amortization and depreciation	452	1,116	1,631
Gain on sale of MRI assets	(2,508)
Goodwill and long-lived asset impairment	6,693	0	27,443
Total operating expenses	32,344	28,488	59,429
Loss from operations	(14,168)	(9,970)	(30,079)
Other (expense) income:
Interest expense	(124)	(63)	(650)
Loss from extinguishment of debt			(1,723)
Interest income	18	10	21
Other expense, net	(106)	(53)	(2,352)
Loss before income tax expense	(14,274)	(10,023)	(32,431)
Income tax (benefit) expense	(18)	76	16
Net loss and comprehensive loss	$ (14,256)	$ (10,099)	$ (32,447)
Net loss per share:
Basic	$ (0.87)	$ (0.63)	$ (2.07)
Diluted	$ (0.87)	$ (0.63)	$ (2.07)
Weighted average number of shares used in computing loss per share:
Basic	16,343	15,932	15,686
Diluted	16,343	15,932	15,686

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2014	$ 62,779	$ 157	$ 209,100	$ (145,063)	$ (1,415)
Beginning Balance, shares at Dec. 31, 2014		15,732,177
Issuance of common stock relative to vesting of restricted stock, net of 13,058, 27,299 and 55,115 shares forfeited for tax obligations in 2015, 2016 and 2017 respectively	(87)	$ 1	(88)
Issuance of common stock relative to vesting of restricted stock, net of 13,058, 27,299 and 55,115 shares forfeited for tax obligations in 2015, 2016 and 2017 respectively, shares		111,700
Issuance of common stock pursuant to stock option plans	$ 366	$ 1	365
Issuance of common stock pursuant to stock option plans, shares	79,472	79,472
Stock-based compensation	$ 2,135		2,135
Net loss	(32,447)			(32,447)
Ending Balance at Dec. 31, 2015	32,746	$ 159	211,512	(177,510)	(1,415)
Ending Balance, shares at Dec. 31, 2015		15,923,349
Issuance of common stock relative to vesting of restricted stock, net of 13,058, 27,299 and 55,115 shares forfeited for tax obligations in 2015, 2016 and 2017 respectively	(114)	$ 3	(117)
Issuance of common stock relative to vesting of restricted stock, net of 13,058, 27,299 and 55,115 shares forfeited for tax obligations in 2015, 2016 and 2017 respectively, shares		261,731
Issuance of common stock pursuant to stock option plans	$ 198	$ 1	197
Issuance of common stock pursuant to stock option plans, shares	75,583	75,583
Stock-based compensation	$ 2,307		2,307
Net loss	(10,099)			(10,099)
Ending Balance at Dec. 31, 2016	25,038	$ 163	213,899	(187,609)	(1,415)
Ending Balance, shares at Dec. 31, 2016		16,260,663
Issuance of common stock relative to vesting of restricted stock, net of 13,058, 27,299 and 55,115 shares forfeited for tax obligations in 2015, 2016 and 2017 respectively	(241)	$ 4	(245)
Issuance of common stock relative to vesting of restricted stock, net of 13,058, 27,299 and 55,115 shares forfeited for tax obligations in 2015, 2016 and 2017 respectively, shares		414,319
Issuance of common stock pursuant to stock option plans	$ 79		79
Issuance of common stock pursuant to stock option plans, shares	36,530	36,530
Stock-based compensation	$ 3,656		3,656
Net loss	(14,256)			(14,256)
Ending Balance at Dec. 31, 2017	$ 14,276	$ 167	$ 217,389	$ (201,865)	$ (1,415)
Ending Balance, shares at Dec. 31, 2017		16,711,512

Consolidated Statements of Sha6

Consolidated Statements of Shareholders' Equity (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Shares forfeited for tax obligations	55,115	27,299	13,058
Common Stock [Member]
Shares forfeited for tax obligations	55,115	27,299	13,058
Additional Paid-in Capital [Member]
Shares forfeited for tax obligations	55,115	27,299	13,058

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flow from operating activities:
Net loss	$ (14,256,000)	$ (10,099,000)	$ (32,447,000)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Amortization	494,000	983,000	1,768,000
Depreciation	995,000	1,322,000	1,580,000
Bad debt provision	45,000	177,000	383,000
Inventory obsolesence reserve	1,052,000	114,000	55,000
Stock-based compensation expense	3,656,000	2,307,000	2,135,000
Amortization of debt discount and debt costs		(23,000)	341,000
Gain from acquisition settlement		(249,000)
Goodwill and long-lived asset impairment	6,693,000	0	27,443,000
Interest on settlement obligations	26,000	82,000	146,000
Deferred tax	8,000	7,000
Loss on disposal of assets	52,000	10,000	125,000
Gain on sale of MRI assets	(2,158,000)
Loss on extinguishment of debt			1,723,000
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	(3,474,000)	2,201,000	1,772,000
Inventory	554,000	482,000	(2,042,000)
Prepaid and other assets	29,000	(504,000)	(197,000)
Accounts payable	(215,000)	(16,000)	(557,000)
Accrued expenses	(505,000)	309,000	(2,060,000)
Deferred revenue	(333,000)	(2,581,000)	(2,068,000)
Total adjustments	6,919,000	4,621,000	30,547,000
Net cash used for operating activities	(7,337,000)	(5,478,000)	(1,900,000)
Cash flow from investing activities:
Additions to patents, technology and other	(5,000)	(12,000)	(40,000)
Additions to property and equipment	(390,000)	(337,000)	(932,000)
Sale of MRI assets	2,850,000
Net cash provided by (used for) investing activities	2,455,000	(355,000)	(2,672,000)
Cash flow from financing activities:
Issuance of common stock for cash, net	0	0	0
Stock option exercises	79,000	198,000	366,000
Taxes paid related to restricted stock issuance	(241,000)	(114,000)	(87,000)
Debt issuance costs	(74,000)
Principal payments of capital lease obligations	(80,000)	(946,000)	(1,397,000)
Proceeds from debt financing	6,000,000
Principal repayment of debt financing, net			(11,250,000)
Net cash provided by (used for) financing activities	5,684,000	(862,000)	(12,368,000)
Increase (decrease) in cash and equivalents	802,000	(6,695,000)	(16,940,000)
Cash and equivalents, beginning of year	8,585,000	15,280,000	32,220,000
Cash and equivalents, end of year	9,387,000	8,585,000	15,280,000
Supplemental disclosure of cash flow information:
Interest paid	79,000	70,000	558,000
Taxes paid	60,000	67,000	128,000
Escrow due from MRI asset sale	350,000
Equipment purchased under capital lease	$ 42,000
VuComp M-Vu CAD [Member]
Cash flow from investing activities:
Acquisition		$ (6,000)
VuComp M-Vu Breast Density Product [Member]
Cash flow from investing activities:
Acquisition			$ (1,700,000)

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(1) Summary of Significant Accounting Policies (a) Nature of Operations and Use of Estimates iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company has grown primarily through acquisitions to become a broad player in the oncology market. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, MRI and CT, and the Xoft System which is an isotope-free cancer treatment platform technology. CAD is reimbursable in the U.S. under federal and most third-party insurance programs. The Company intends to continue the extension of its image analysis and clinical decision support solutions for mammography, MRI and CT imaging. iCAD believes that advances in digital imaging techniques should bolster its efforts to develop additional commercially viable CAD/advanced image analysis and workflow products. The Company’s management believes that early detection in combination with earlier targeted intervention will provide patients and care providers with the best tools available to achieve better clinical outcomes resulting in a market demand that will drive top line growth. The Company’s headquarters are located in Nashua, New Hampshire, with manufacturing and contract manufacturing facilities in New Hampshire and Massachusetts, and an operations, research, development, manufacturing and warehousing facility in San Jose, California. The Company operates in two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products, and the Therapy segment consists of radiation therapy products. The Company sells its products throughout the world through its direct sales organization as well as through various OEM partners, distributors and resellers. See Note 8 for segment, major customer and geographical information. The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. In January 2018 the Company adopted a plan to discontinue offering radiation therapy professional services to practices that provide the Company’s electronic brachytherapy solution for the treatment of non-melanoma (b) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xoft, Inc. and Xoft Solutions, LLC. All material inter-company transactions and balances have been eliminated in consolidation. (c) Cash and cash equivalents The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 days or less, which are unrestricted as to withdrawal. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage is $250,000 per depositor at each financial institution, and the Company’s non-interest (d) Financial instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable. Due to their short term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2017 and 2016. (e) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are customer obligations due under normal trade terms. Credit limits are established through a process of reviewing the financial history and stability of each customer. The Company performs continuing credit evaluations of its customers’ financial condition and generally does not require collateral. The Company’s policy is to maintain allowances for estimated losses from the inability of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may potentially be uncollectible. The Company includes any accounts receivable balances that it determines may likely be uncollectible, along with a general reserve for estimated probable losses based on historical experience, in its overall allowance for doubtful accounts. An amount would be written off against the allowance after all attempts to collect the receivable had failed. Based on the information available, the Company believes the allowance for doubtful accounts as of December 31, 2017 and 2016 is adequate. The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2017 (in thousands): 2017 2016 2015 Balance at beginning of period $ 172 $ 236 $ 203 Additions charged to costs and expenses 45 177 383 Reductions (110 ) (241 ) (350 ) Balance at end of period $ 107 $ 172 $ 236 (f) Inventory Inventory is valued at the lower of cost or net realizable value, with cost determined by the first-in, first-out As of December 31, 2017 2016 Raw materials $ 992 $ 2,503 Work in process 63 75 Finished Goods 1,068 1,149 Inventory $ 2,123 $ 3,727 (g) Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, if shorter, for leasehold improvements (see below). Estimated life Equipment 3-5 Leasehold improvements 3-5 Furniture and fixtures 3-5 Marketing assets 3-5 (h) Goodwill In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350-20, “Intangibles—Goodwill and Other” 350-20”), Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company records an impairment charge when such assessment indicates that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of reporting units. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. In January 2018 the Company adopted a plan to discontinue offering radiation therapy professional services to practices that provide the Company’s electronic brachytherapy solution for the treatment of non-melanoma The Company elected to early adopt ASU 2017-04, 2017-04”) 2017-04 As a result of the underperformance of the Therapy reporting unit as compared to expected future results, the Company determined there was a triggering event in the third quarter of 2017. As a result, the Company completed an interim impairment assessment. The interim test resulted in the fair value of the Therapy reporting unit being less than the carrying value of the reporting unit. The fair value of the Therapy reporting unit was $3.5 million and the carrying value was $7.5 million. The deficiency of $4.0 million was recorded as an impairment charge in the third quarter ended September 30, 2017. The Company did not identify a triggering event within the Detection reporting unit and accordingly did not perform an interim test. As a result of external factors and general uncertainty related to reimbursement for non-melanoma The Company determines the fair value of reporting units based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. This approach was selected as it measures the income producing assets, primarily technology and customer relationships. This method estimates the fair value based upon the ability to generate future cash flows, which is particularly applicable when future profit margins and growth are expected to vary significantly from historical operating results. The Company uses internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for the reporting unit. Accordingly, actual results can differ from those assumed in the forecasts. Discount rates are derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting unit to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts. Other significant assumptions include terminal value margin rates, future capital expenditures, and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to the application of these assumptions to this analysis, the income approach provides a reasonable estimate of the fair value of the Therapy reporting unit. The Company performed the annual impairment assessment at October 1, 2017 and compared the fair value of each of reporting unit to its carrying value as of this date. Fair value exceeded the carrying value for the Detection reporting unit, and the carrying value approximated fair value of the Therapy reporting unit after the impairment as of September 30, 2017. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities, to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment. The Company determines the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on our most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in our forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weights the methodologies appropriately. In April 2015, the Company acquired VuComp’s M-Vu ® In January 2016, the Company completed the acquisition of VuComp’s M-Vu In December 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. The Company conveyed to Buyer all right, title and interest to certain intellectual property relating to the VersaVue Software and the DynaCAD product and related assets. As a result of the agreement, the Company determined that it had assets held for sale as of December 31, 2016 and the sale constituted the sale of a business. As of December 31, 2016, the Company allocated $394,000 of goodwill to assets held for sale. The allocation was based on the fair value of the assets sold relative to the fair value of the Detection reporting unit as of the date of the agreement. A rollforward of goodwill activity by reportable segment is as follows (in thousands): Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at December 31, 2015 8,463 5,735 14,198 Acquisition of VuComp 293 — 293 Sale of MRI assets (394 ) — (394 ) Balance at December 31, 2016 8,362 5,735 14,097 Impairment — (5,735 ) (5,735 ) Balance at December 31, 2017 $ 8,362 $ — $ 8,362 Accumulated Goodwill 699 6,270 54,906 Fair value allocation 7,663 13,446 — Accumulated impairment — (19,716 ) (46,544 ) Balance at December 31, 2017 $ 8,362 $ — $ 8,362 (i) Long Lived Assets In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360-10-35 360-10-35-21, • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). In accordance with ASC 360-10-35-17, The Company completed an interim goodwill impairment assessment for the Therapy reporting unit in the third quarter of 2017 and noted that there was an impairment of goodwill. As a result, the Company determined this was a triggering event to review long-lived assets for impairment. Accordingly, the Company completed an analysis pursuant to ASC 360-10-35-17 The Company also completed a goodwill assessment in the fourth quarter of 2017, and in connection with that assessment, the Company completed an analysis pursuant to ASC 360-10-35-17 The Company did not record any impairment charges for the year ended December 31, 2016. As a result of external factors and general uncertainty related to reimbursement for the treatment of NMSC, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for impairment in 2015. In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the Asset Group. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values, and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges. Intangible assets subject to amortization consist primarily of patents, technology, customer relationships and trade names purchased in the Company’s previous acquisitions. These assets, which include assets from the acquisition of the assets of VuComp, DermEbx and Radion and the acquisition of Xoft, Inc., are amortized on a straight-line basis consistent with the pattern of economic benefit over their estimated useful lives of 5 to 15 years. A summary of intangible assets for 2017 and 2016 are as follows (in thousands): 2017 2016 Weighted Gross Carrying Amount Patents and licenses $ 556 $ 583 5 years Technology 8,257 9,567 10 years Customer relationships 292 292 7 years Tradename 259 259 10 years Total amortizable intangible assets 9,364 10,701 Accumulated Amortization Patents and licenses $ 503 $ 477 Technology 6,610 6,754 Customer relationships 61 28 Tradename 259 259 Total accumulated amortization 7,433 7,518 Total amortizable intangible assets, net $ 1,931 $ 3,183 Amortization expense related to intangible assets was approximately $494,000, $983,000 and $1,768,000 for the years ended December 31, 2017, 2016, and 2015, respectively. Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): For the years ended December 31: Estimated 2018 $ 417 2019 379 2020 305 2021 228 2022 299 Thereafter 303 $ 1,931 (j) Revenue Recognition The Company recognizes revenue primarily from the sale of products, services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement. The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, Multiple-Deliverable Revenue Arrangement 2009-13”) No. 2009-14, Certain Arrangements That Contain Software Elements 2009-14”) 985-605, “Software” 985-605”). Leases” The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references. If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process. The Company has determined that iCAD’s digital and film based sales generally follow the guidance of FASB ASC Topic 605 “ Revenue Recognition 2009-14. 2009-13. Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, Services (k) Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house (l) Warranty Costs The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including the cost of product returns during the warranty period. Warranty provisions and claims for the years ended December 31, 2017, 2016 and 2015, were as follows (in thousands): 2017 2016 2015 Beginning accrual balance $ 11 $ 19 $ 14 Warranty provision 49 47 54 Usage (50 ) (55 ) (49 ) Ending accrual balance $ 10 $ 11 $ 19 The warranty accrual above includes long-term warranty obligations of $0, $0 and $2,000 for the years ended December 31, 2017, 2016 and 2015 respectively. (m) Engineering and Product Development Costs Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials which are expensed as incurred. (n) Advertising Costs The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2017, 2016 and 2015 was approximately $990,000, $955,000 and $950,000 respectively. (o) Net Loss per Common Share The Company follows FASB ASC 260-10, A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2017 2016 2015 Net loss available to common shareholders $ (14,256 ) $ (10,099 ) $ (32,447 ) Basic shares used in the calculation of earnings per share 16,343 15,932 15,686 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 16,343 15,932 15,686 Net loss per share : Basic $ (0.87 ) $ (0.63 ) $ (2.07 ) Diluted $ (0.87 ) $ (0.63 ) $ (2.07 ) The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive: 2017 2016 2015 Common stock options 1,465,115 1,425,348 1,571,998 Restricted Stock 415,147 511,398 516,396 1,880,262 1,936,746 2,088,394 Restricted common stock can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares were excluded from the computation of basic loss per share as these shares are not considered outstanding until vested. (p) Income Taxes The Company follows the liability method under ASC Topic 740, “Income Taxes”, (“ASC 740”). The primary objectives of accounting for taxes under ASC 740 are to (a) recognize the amount of tax payable for the current year and (b) recognize the amount of deferred tax liability or asset for the future tax consequences of events that have been reflected in the Company’s financial statements or tax returns. The Company has provided a full valuation allowance against its deferred tax assets at December 31, 2017 and 2016, as it is more likely than not that the deferred tax asset will not be realized. Any subsequent changes in the valuation allowance will be recorded through operations in the provision (benefit) for income taxes. ASC 740-10 740-10 de-recognition, (q) Stock-Based Compensation The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company may grant to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may grant restricted stock to employees and directors. The underlying shares of the restricted stock grant are not issued until the shares vest, and compensation expense is based on the stock price of the shares at the time of grant. The Company follows FASB ASC Topic 718, “Compensation – Stock Compensation” (“ASC 718”), for all stock-based compensation. Under this application, the Company is required to record compensation expense over the vesting period for all awards granted. The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, the risk free rate, expected dividend yield, and the number of options that will be forfeited prior to the completion of their vesting requirements. The fair value of restricted stock is determined based on the stock price of the underlying option on the date of the grant. The Company granted performance based restricted stock during 2016 based on achievement of certain revenue targets. Compensation cost for performance based restricted stock requires significant judgment regarding probability of the performance objectives and compensation cost is re-measured Application of alternative assumptions could produce significantly different estimates of the fair value of stock-based compensation and consequently, the related amounts recognized in the Consolidated Statements of Operations. (r) Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurement and Disclosures” (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The money market funds are included in cash and cash equivalents in the accompanying balance sheet, and are considered a level 1 investment as they are valued at quoted market prices in active markets. The following table sets forth Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2017 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 8,853 $ — $ — $ 8,853 Total Assets $ 8,853 $ — $ — $ 8,853 Fair value measurements using: (000’s) as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,622 $ — $ — $ 6,622 Total Assets $ 6,622 $ — $ — $ 6,622 Items Measured at Fair Value on a Nonrecurring Basis Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. In 2015 the Company recorded a $27.4 million impairment consisting of $14.0 million related to goodwill and $13.4 million related to long-lived assets as discussed in Note (h) and Note (i) and re-measured (s) Recently Issued and Recently Adopted Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, 2014-09, 2016-08, 2016-10, No. 2014-09. 2014-09 one-year The Company has performed an assessment of its revenue streams and customer classes. During the fourth quarter of 2017, the Company completed its implementation plan and finalized contract reviews and detailed policy drafting. The Company will adopt the guidance effective January 1, 2018 using the modified retrospective approach, by recognizing the cumulative effect of initially applying the new standard as an increase to the opening balance of retained earnings. We expect this adjustment to be less than $0.1 million and do not expect a material impact on our revenue recognition practices on an ongoing basis. The Company will adopt certain practical expedients and make certain policy elections related to the accounting for significant finance components, sales taxes, shipping and handling, costs to obtain a contract, and immaterial promised goods or services, which will mitigate certain impacts of adopting Topic 606. The immaterial impact of adopting Topic 606 primarily relates to (a) the deferral of commissions on our long-term service arrangements and warranty periods greater than one year, which previously were expensed as incurred but under the amendments to ASC 340-40 Leases non-lease The impact to our results is not material because the analysis of our contracts under the new revenue recognition standard supports the recognition of revenue at a point in time for product sales and over time for service contracts (as well as for the lease components of certain CAD products), which is consistent with our current revenue recognition model. A significant portion of our revenue is generated from sales of cancer detection products and cancer therapy systems, and revenue is recognized when delivery has occurred as our performan

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisitions	(2) Acquisitions Acquisition of VuComp Cancer detection portfolio On January 13, 2016, the Company completed the acquisition of the VuCOMP cancer detection portfolio, including the M-Vu As noted below, the Company acquired VuComp’s M-Vu Amount (000’s) Cash $ 6 Acquisition litigation settlement 249 Purchase price $ 255 The amount allocated to the acquired assets was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. The following is a summary of the allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life: Amount (000’s) Estimated Current assets $ 84 Property and equipment 65 3 Years Identifiable intangible assets 699 1-10 Years Goodwill 293 Current liabilities (280 ) Long-term liabilities (606 ) Purchase price $ 255 The assets obtained in the acquisition of VuComp’s M-Vu M-Vu Acquisition of VuComp M-Vu On April 29, 2015, pursuant to the terms of the Asset Purchase Agreement with VuComp, the Company purchased VuComp’s M-Vu Business Combinations The amount allocated to the acquired assets was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. The acquired technology is being amortized over the estimated useful life of approximately eight years and nine months from the closing of the transaction. The following is a summary of the allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life (in thousands): Amount Estimated Amortizable Developed Technology $ 900 8 years 9 months Goodwill 800 Purchase price $ 1,700 The assets obtained in the acquisition of VuComp’s M-Vu

Sale of MRI Assets

Sale of MRI Assets	12 Months Ended
	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Sale of MRI Assets	(3) Sale of MRI Assets In December 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. In accordance with the agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction on January 30, 2017 less a holdback reserve of $350,000 for a net of approximately $2.9 million. The holdback reserve of $350,000 has been recorded as an asset in other assets and will be paid to the Company within eighteen months from the closing date, less any amounts, if any, due and payable or reserved under the indemnification provisions in the Asset Purchase agreement. The Company determined the sale constituted the sale of a business in accordance with ASC 805. The Company performed an evaluation to determine if the sale constituted discontinued operations and concluded that the sale did not represent a major strategic shift, and accordingly it was not considered to be discontinued operations. In connection with the transaction, the Company allocated $394,000 of goodwill which was a component of the gain on the sale. The allocation was based on the fair value of the assets sold relative to the fair value of the Detection reporting unit as of the date of the agreement, based on the guidance from ASC 350-20-40-3. The value of the net assets sold is as follows (in thousands): Assets Accounts Receivable $ 116 Intangible assets 810 Allocated Goodwill 394 Total Assets $ 1,320 Liabilities Deferred Revenue $ 746 Total Liabilities $ 746 Net Assets Sold $ 574 In connection with the sale the Company agreed to provide certain transition services to Invivo. The fair value of the transition services were determined based on the cost to provide plus a reasonable profit margin and have been recognized as revenue over the term of approximately ninety days from the closing date. The Company recorded a gain of $2.5 million as of January 30, 2017. The components of the gain on the sale are as follows (in thousands): Gain on Sale Cash received $ 2,850 Holdback reserve 350 Fair value of transition services (118 ) Net Assets sold (574 ) Total $ 2,508

Financing Arrangements

Financing Arrangements	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Financing Arrangements	(4) Financing Arrangements On August 7, 2017, the Company entered into a Loan and Security Agreement, which was modified by the First Loan Modification Agreement dated March 22, 2018 (the “Loan Agreement”) with Silicon Valley Bank (the “Bank”) that provides an initial term loan facility (amounts borrowed thereunder, the “Term Loan”) of $6.0 million and a $4.0 million revolving line of credit (amounts borrowed thereunder, the “Revolving Loans”). The Company also has the option to borrow an additional $3.0 million Term Loan under the Loan Agreement, subject to meeting a Detection revenue minimum of at least $21.5 million for a trailing twelve month period ending prior to July 30, 2019. The Company will begin repayment of the first tranche of the Term Loan on September 1, 2018 in 36 equal monthly installments of principal. If the adjusted EBITDA minimum of $(750,000) for a trailing three month period ending between March 22, 2018 and July 31, 2018 (the “Adjusted EBITDA Event”) is met, the Company will begin repayment of the Term Loans beginning on March 1, 2019 in which case the Company would make 30 equal monthly installments of principal. The Company will begin repayment of the second tranche of the Term Loan on October 1, 2019 and make 30 equal monthly installments of principal. The outstanding Revolving Loans will accrue interest at a floating per annum rate equal to 1.50% above the prime rate for periods when the ratio of the Company’s unrestricted cash to the Company’s outstanding liabilities to the Bank plus the amount of the Company’s total liabilities that mature within one year is at least 1.25 to 1.0. At all other times, the interest rate shall be 0.50% above the prime rate. The outstanding Term Loans will accrue interest at a floating per annum rate equal to the prime rate. The maturity date of the Revolving Loans and the Term Loans is March 1, 2022. However, the maturity date will become April 30, 2019, April 30, 2020 or April 30, 2021 if, on or before March 15, 2019, or 2020 or 2021, as applicable, the Company does not agree in writing to the Detection revenue and adjusted EBITDA covenant levels proposed by the Bank with respect to the upcoming applicable calendar year. If the Revolving Loans are paid in full and the Loan Agreement is terminated prior to the maturity date, then the Company will pay to the Bank a termination fee in an amount equal to two percent (2.0%) of the maximum revolving line of credit. If the Company prepays the Term Loans prior to the maturity date, then the Company will pay to the Bank an amount equal to 1.0%-3.0% Obligations to the Bank under the Loan Agreement or otherwise are secured by a first priority security interest in substantially all of the assets, including intellectual property, accounts, receivables, equipment, general intangibles, inventory and investment property, and all of the proceeds and products of the foregoing, of each of the Company and Xoft, Inc. and Xoft Solutions LLC, wholly-owned subsidiaries of the Company. In connection with the Loan Agreement, the Company incurred approximately $74,000 of closing costs. In accordance with ASU 2015-03 The current repayment schedule for the term loan is based on repayment beginning on September 1, 2018. If the Adjusted EBITDA Event occurs, the Company could elect to defer repayment until October 2019. The carrying value of the Term Loan (net of debt issuance costs) as of December 31, 2017 is as follows (in thousands): December 31, 2017 Principal Amount of Term Loan $ 6,000 Unamortized closing costs (64 ) Carrying amount of Term Loan 5,936 Less current portion of Term Loan (817 ) Notes payable long-term portion $ 5,119 Principal and interest payments are as follows (in thousands): Fiscal Year Amount Due 2018 $ 1,086 2019 $ 2,183 2020 $ 2,097 2021 $ 1,183 Total $ 6,549 The following amounts are included in interest expense in our consolidated statement of operations for the years ended December 31, 2017, 2016 and 2015 (in thousands): December 31, 2017 December 31, 2016 December 31, 2015 Cash interest expense $ 98 $ — $ 163 Non-cash $ — $ — $ 254 Amortization of debt costs 9 — 13 Amortization of settlement obligations 26 82 146 Interest expense capital lease 1 70 220 Capital lease—fair value amortization (10 ) (89 ) (146 ) Total interest expense $ 124 $ 63 $ 650 The amortization of debt costs represents the costs incurred with the financing, which is primarily the closing costs which have been capitalized and will be expensed using the effective interest method. The amortization of the settlement obligations represents the interest associated with the settlement agreement for Zeiss. See Note 9(f) to our Consolidated Financial Statements.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	(5) Accrued Expenses Accrued expenses consist of the following at December 31 (in thousands): 2017 2016 Accrued salary and related expenses $ 1,388 $ 1,878 Accrued accounts payable 2,523 2,269 Accrued professional fees 418 316 Accrued short term settlement costs — 474 Other accrued expenses 70 48 Deferred rent 76 3 $ 4,475 $ 4,988

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Equity	(6) Stockholders’ Equity (a) Stock Options The Company has six stock option or stock incentive plans, which are described as follows: The 2002 Stock Option Plan (the “2002 Plan”). The 2002 Plan was adopted by the Company’s stockholders in June 2002. The 2002 Plan provides for the granting of non-qualifying Non-qualifying The 2004 Stock Incentive Plan (the “2004 Plan”). The 2004 Plan was adopted by the Company’s stockholders in June 2004. The 2004 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. The 2004 Plan provides for the granting of non-qualifying Non-qualifying The 2005 Stock Incentive Plan (the “2005 Plan”). The 2005 Plan was adopted by the Company’s stockholders in June 2005. The 2005 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. The 2005 Plan provides for the granting of non-qualifying Non-qualifying The 2007 Stock Incentive Plan (the “2007 Plan”). The 2007 Plan was adopted by the Company’s stockholders in July 2007 and amended in June 2009. The 2007 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. Awards may be granted singly, in combination, or in tandem. Subject to anti-dilution adjustments as provided in the 2007 Plan, (i) the 2007 Plan provides for a total of 1,050,000 shares of the Company’s common stock to be available for distribution pursuant to the 2007 Plan, and (ii) the maximum number of shares of the Company’s common stock with respect to which stock options, restricted stock, deferred stock, or other stock-based awards may be granted to any participant under the 2007 Plan during any calendar year or part of a year may not exceed 160,000 shares. The 2007 Plan provides that it will be administered by the Company’s Board of Directors (“Board”) or a committee of two or more members of the Board appointed by the Board. The administrator will generally have the authority to administer the 2007 Plan, determine participants who will be granted awards under the 2007 Plan, the size and types of awards, the terms and conditions of awards and the form and content of the award agreements representing awards. Awards under the 2007 Plan may be granted to employees, directors, consultants and advisors of the Company and its subsidiaries. However, only employees of the Company and its subsidiaries will be eligible to receive options that are designated as incentive stock options. With respect to options granted under the 2007 Plan, the exercise price must be at least 100% (110% in the case of an incentive stock option granted to a 10% stockholder) of the fair market value of the common stock subject to the award, determined as of the date of grant. Restricted stock awards are shares of common stock that are awarded subject to the satisfaction of the terms and conditions established by the administrator. In general, awards that do not require exercise may be made in exchange for such lawful consideration, including services, as determined by the administrator. At December 31, 2017, there were no shares available for issuance under the 2007 Plan. The 2012 Stock Incentive Plan (the “2012 Plan”). The 2012 Plan was adopted by the Company’s stockholders in May 2012 and amended in May 2014. The 2012 Plan, as amended, provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. Awards may be granted singly, in combination, or in tandem. Subject to anti-dilution adjustments as provided in the amended 2012 Plan, (i) the amended 2012 Plan provides for a total of 1,600,000 shares of the Company’s common stock to be available for distribution pursuant to the amended 2012 Plan, and (ii) the maximum number of shares of the Company’s common stock with respect to which stock options, restricted stock, deferred stock, or other stock-based awards may be granted to any participant under the amended 2012 Plan during any calendar year or part of a year may not exceed 250,000 shares. The 2012 Plan provides that it will be administered by the Company’s Board of Directors (“Board”) or a committee of two or more members of the Board appointed by the Board. The administrator will generally have the authority to administer the 2012 Plan, determine participants who will be granted awards under the 2012 Plan, the size and types of awards, the terms and conditions of awards and the form and content of the award agreements representing awards. Awards under the 2012 Plan may be granted to employees, directors, consultants and advisors of the Company and its subsidiaries. However, only employees of the Company and its subsidiaries will be eligible to receive options that are designated as incentive stock options. With respect to options granted under the 2012 Plan, the exercise price must be at least 100% (110% in the case of an incentive stock option granted to a 10% stockholder) of the fair market value of the common stock subject to the award, determined as of the date of grant. Restricted stock awards are shares of common stock that are awarded subject to the satisfaction of the terms and conditions established by the administrator. In general, awards that do not require exercise may be made in exchange for such lawful consideration, including services, as determined by the administrator. At December 31, 2017, there were 222,377 shares available for issuance under the 2012 Plan. The 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan was adopted by the Company’s stockholders in May 2016. The 2016 Plan provides for the grant of any or all of the following types of awards: (a) non-qualified Subject to anti-dilution adjustments as provided in the 2016 Plan, (i) the 2016 Plan provides for a total of 1,700,000 shares of the Company’s common stock to be available for distribution pursuant to the 2016 Plan, and (ii) the maximum number of shares of the Company’s common stock with respect to which stock options or stock appreciation rights may be granted to any one individual under the 2016 Plan during any one calendar year period may not exceed 1,000,000 shares. No more than 1,000,000 shares of common stock may be issued in the form of incentive stock options and no more than 50,000 shares of stock may be issued pursuant to awards to non-employee The 2016 Plan provides that it will be administered by the Company’s Compensation Committee. The Compensation Committee has the authority to administer the 2016 Plan, determine participants, from among the individuals eligible for awards, who will be granted awards under the 2016 Plan, make any combination of awards to participants and determine the specific terms and conditions of awards subject to the 2016 Plan. Awards under the 2016 Plan may be granted to full or part-time officers, employees, non-employee With respect to stock options granted under the 2016 Plan, the exercise price will be determined by the Compensation Committee but may not be less than 100% of the fair market value of the common stock subject to the award, determined as of the date of grant. Regarding incentive stock options, including that the aggregate grant date fair market value of the shares of stock with respect to which incentive stock options granted under the 2016 Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any incentive stock option exceeds this limit, it shall constitute a non-qualified stock option. Restricted stock awards are shares of common stock that are awarded subject to the satisfaction of the terms and conditions established by the Compensation Committee. In general, awards that do not require exercise may be made in exchange for such lawful consideration, including services, as determined by the Compensation Committee. At December 31, 2017, there were 815,500 shares available for issuance under the 2016 Plan. A summary of stock option activity for all stock option plans is as follows: Number of Weighted Average Weighted Average Outstanding, January 1, 2015 1,417,887 $ 4.34 Granted 363,239 $ 6.58 Exercised (79,472 ) $ 4.60 Forfeited (129,656 ) $ 7.38 Outstanding, December 31, 2015 1,571,998 $ 5.05 Granted 127,500 $ 5.46 Exercised (75,583 ) $ 2.62 Forfeited (198,567 ) $ 6.19 Outstanding, December 31, 2016 1,425,348 $ 5.05 Granted 200,813 $ 4.14 Exercised (36,530 ) $ 2.18 Forfeited (124,516 ) $ 4.71 Outstanding, December 31, 2017 1,465,115 $ 5.03 5.3 years Exercisable at December 31, 2015 1,087,725 $ 4.33 Exercisable at December 31, 2016 1,054,211 $ 4.71 Exercisable at December 31, 2017 1,301,651 $ 4.95 5.0 years Available for future grants at December 31, 2017 from all plans: 1,037,877 The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Years Ended December 31, 2017 2016 2015 Cost of revenue $ 5 $ 6 $ 14 Engineering and product development 715 329 223 Marketing and sales 1,003 677 659 General and administrative expense 1,933 1,295 1,239 $ 3,656 $ 2,307 $ 2,135 As of December 31, 2017, there was $2.0 million of total unrecognized compensation costs related to unvested options and restricted stock. That cost is expected to be recognized over a weighted average period of 1.1 years. Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Years Ended December 31, 2017 2016 2015 Average risk-free interest rate 1.61 % 0.98 % 0.97 % Expected dividend yield None None None Expected life 3.5 years 3.5 years 3.5 years Expected volatility 64.2% to 72.0 % 68.5% to 75.3 % 60.5% to 75.2 % Weighted average exercise price $ 4.14 $ 5.46 $ 6.58 Weighted average fair value $ 1.99 $ 2.66 $ 3.17 The Company’s 2017, 2016 and 2015, average expected volatility and average expected life is based on the average of the Company’s historical information. The risk-free rate is based on the rate of U.S. Treasury zero-coupon issues with a remaining term equal to the expected life of option grants. The Company has paid no dividends on its common stock in the past and does not anticipate paying any dividends in the future. Intrinsic values of options (in thousands) and the closing market price used to determine the intrinsic values are as follows: Years Ended December 31, 2017 2016 2015 Outstanding $ 449 $ 409 $ 1,910 Exercisable 442 409 1,610 Exercised 79 201 317 stock price at 12/31 $ 3.44 $ 3.24 $ 5.17 (b) Restricted Stock The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from grant date. The Company granted a total of 162,500 shares of performance based restricted stock during 2016 with performance measured on meeting a revenue target based on growth for fiscal year 2017 and vesting in three equal installments with the first installment vesting upon measurement of the goal. In addition, a maximum of 108,333 additional shares are available to be earned based on exceeding the revenue goal. The Company expects approximately 190,000 shares to be earned under the performance grant with 63,200 shares vested on the measurement date and approximately 63,200 shares vesting on the second and third anniversary of the initial vesting. A summary of restricted stock activity for all equity incentive plans is as follows: Years Ended December 31, 2017 2016 2015 Beginning outstanding balance 511,398 516,396 309,317 Granted 394,599 345,778 352,666 Vested (469,434 ) (289,030 ) (124,758 ) Forfeited (21,416 ) (61,746 ) (20,829 ) Ending outstanding balance 415,147 511,398 516,396 Intrinsic values of restricted stock (in thousands) and the closing market price used to determine the intrinsic values are as follows: Years Ended December 31, 2017 2016 2015 Outstanding $ 1,428 $ 1,657 $ 2,670 Vested 1,615 936 645 stock price at 12/31 $ 3.44 $ 3.24 $ 5.17

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(7) Income Taxes The components of income tax expense for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): 2017 2016 2015 Current provision (benefit): Federal $ — $ — $ — State (26 ) 69 95 $ (26 ) $ 69 $ 95 Deferred provision: Federal $ 7 $ 6 $ (65 ) State 1 1 (14 ) $ 8 $ 7 $ (79 ) Total $ (18 ) $ 76 $ 16 A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31, 2017, 2016 and 2015 is as follows: 2017 2016 2015 Federal statutory rate 34.0 % 34.0 % 34.0 % State income taxes, net of federal benefit 1.4 % 2.8 % 2.5 % Net state impact of deferred rate change (0.3 %) 0.2 % (0.1 %) Stock compensation expense (1.9 %) (3.2 %) (0.7 %) Tax amortization on goodwill (0.1 %) (0.1 %) 0.2 % Goodwill impairment (13.7 %) 0.0 % (10.0 %) Other permanent differences (0.4 %) (0.4 %) (0.1 %) Change in valuation allowance 97.4 % (37.3 %) (26.6 %) Tax credits 1.5 % 3.2 % 0.9 % Federal Rate Change (133.5 %) 0.0 % 0.0 % Accrual to TR (0.7 %) 0.0 % 0.0 % Increase Xoft NOLs under 382 Study 16.2 % 0.0 % 0.0 % Effective income tax (0.10 %) (0.8 %) 0.1 % Deferred tax assets and liabilities are recognized for the expected future tax consequences of net operating loss carryforwards, tax credit carryforwards and temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that the deferred tax assets will not be realized. Deferred income taxes reflect the impact of “temporary differences” between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. The Company has fully reserved the net deferred tax assets, as it is more likely than not that the deferred tax assets will not be utilized. Deferred tax assets (liabilities) are composed of the following at December 31 (in thousands): 2017 2016 Inventory (Section 263A) $ 287 $ 418 Inventory reserves 305 105 Receivable reserves 27 65 Other accruals 224 434 Deferred revenue 129 215 Accumulated depreciation/amortization 320 477 Stock options 1,901 2,558 Developed technology 2,201 3,594 Tax credits 3,130 3,090 NOL carryforward 31,113 40,865 Net deferred tax assets 39,637 51,821 Valuation allowance (39,637 ) (51,821 ) Goodwill tax amortization (14 ) (7 ) Deferred tax liability $ (14 ) $ (7 ) The decrease in the net deferred tax assets and corresponding valuation allowance during the year ended December 31, 2017 related primarily to the decrease in corporate tax rate from 34% to 21% starting on January 1, 2018. The increase in net deferred tax assets and corresponding valuation allowance during the year ended December 31, 2016 is primarily attributable to additional net operating losses, additional research and development credits, and differences in amortization periods on the Company’s intangible assets. The Company completed an asset acquisition in January 2016 which resulted in $293,307 of goodwill. For book purposes, the goodwill was classified as an indefinite lived asset and tested for impairment each year. For tax, the Company is allowed amortization expense over a 15 year life. Due to the indefinite life of the asset for book purposes, the Company could not assume there would be a deferred tax asset available to offset the liability in future years. This created a tax expense equal to the tax effected amount of tax amortization, or $7,434 in 2017 and $6,844 in 2016. As of December 31, 2017, the Company has net operating loss carryforwards totaling approximately $131.2 million expiring between 2019 and 2037. A portion of the total net operating loss carryforwards amounting to approximately $54.0 million relate to the acquisition of Xoft, Inc. As of December 31, 2017, the Company has provided a valuation allowance for its net operating loss carryforwards due to the uncertainty of the Company’s ability to generate sufficient taxable income in future years to obtain the benefit from the utilization of the net operating loss carryforwards. In the event of a deemed change in control, an annual limitation imposed on the utilization of the net operating losses may result in the expiration of all or a portion of the net operating loss carryforwards. There were no net operating losses utilized for the years ended December 31, 2017 or 2016. The Company currently has approximately $9.9 million (including approximately $8.5 million that relate to Xoft, Inc.) in net operating losses that are subject to limitations, of which approximately $2.0 million (including approximately $656,000 that relates to Xoft, Inc.) can be used annually through 2029. The Company has available tax credit carryforwards (adjusted to reflect provisions of the Tax Reform Act of 1986) to offset future income tax liabilities totaling approximately $3.1 million. The tax credits related to Xoft have been fully reserved for and as a result no deferred tax asset has been recorded. The credits expire in various years through 2037. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of December 31, 2017 and 2016, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations were required under ASC 740-10. The Company’s practice is to recognize interest and penalty expenses related to uncertain tax positions in income tax expense, which was zero for the years ended December 31, 2017, 2016 and 2015. The Company files United States federal and various state income tax returns. Generally, the Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. The Company completed an examination by the Internal Revenue Service with respect to the 2008 tax year in January 2011, which resulted in no changes to the tax return originally filed. The Company is not under examination by any other federal or state jurisdiction for any tax year. The Company does not anticipate that it is reasonably possible that unrecognized tax benefits as of December 31, 2017 will significantly change within the next 12 months. On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (“TCJA”) tax reform legislation. This legislation makes significant change in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate tax rate from the current rate of 34% down to 21% starting on January 1, 2018. As a result of the enacted law, the Company was required to revalue deferred tax assets and liabilities at the 21%. This revaluation resulted in a provision of $19.1 million to income tax expense in continuing operations and a corresponding reduction in the valuation allowance. As a result, there was no impact to the Company’s income statement as a result of reduction in tax rates. The other provisions of the TCJA did not have a material impact on our consolidated financial statements. Our preliminary estimate of the TCJA and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management’s analysis related to certain matters, such as developing interpretations of the provisions of the TCJA, changes to certain estimates and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the TCJA may require further adjustments and changes in our estimates. The final determination of the TCJA and the remeasurement of our deferred assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the TCJA.

Segment Reporting, Geographical

Segment Reporting, Geographical Information and Major Customers	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment Reporting, Geographical Information and Major Customers	(8) Segment Reporting, Geographical Information and Major Customers (a) Segment Reporting In accordance with FASB Topic ASC 280, “ Segments The Company’s CODM is the Chief Executive Officer (“CEO”). Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments: Cancer Detection and Cancer Therapy. The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy (“Axxent”) products, and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring items (“Adjusted EBITDA”) of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no intersegment revenues. We do not track our assets by operating segment and our CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands, including prior periods which have been presented for consistency): Year Ended December 31, 2017 2016 2015 Segment revenues: Detection $ 18,310 $ 17,133 $ 19,243 Therapy 9,792 9,205 22,311 Total Revenue $ 28,102 $ 26,338 $ 41,554 Segment gross profit: Detection $ 16,218 $ 15,113 $ 16,019 Therapy 1,958 3,405 13,331 Segment gross profit $ 18,176 $ 18,518 $ 29,350 Segment operating income (loss): Detection $ 6,401 $ 5,694 $ 7,233 Therapy (15,102 ) (7,752 ) (28,405 ) Segment operating income (loss) $ (8,701 ) $ (2,058 ) $ (21,172 ) General, administrative, depreciation and amortization expense $ (7,975 ) $ (7,912 ) $ (8,907 ) Interest expense (124 ) (63 ) (650 ) Gain on sale of MRI assets 2,508 — — Other income 18 10 21 Loss on debt extinguishment — — (1,723 ) Loss before income tax $ (14,274 ) $ (10,023 ) $ (32,431 ) Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands): Detection depreciation and amortization Depreciation $ 172 $ 223 $ 220 Amortization 246 696 532 Therapy depreciation and amortization Depreciation $ 768 $ 970 $ 1,142 Amortization 222 252 1,213 (b) Geographic Information The Company’s sales are made to customers, distributors and dealers of mammography, electronic brachytherapy equipment and other medical equipment, and to foreign distributors of mammography and electronic brachytherapy equipment. Export sales to a single country did not exceed 10% of total revenue in any year. Total export sales were approximately $3.9 million or 14% of total revenue in 2017, $2.3 million or 9% of total revenue in 2016 and $2.3 million or 6% of total revenue in 2015. As of December 31, 2017 and 2016, the Company had outstanding receivables of $2.1 million and $0.3 million, respectively, from distributors and customers of its products who are located outside of the U.S. (c) Major Customers The Company had one major customer, GE Healthcare, with revenues of approximately $7.1 million in 2017, $3.9 million in 2016, and $4.1 million in 2015 or 25%, 15%, and 10% of total revenue, respectively. Cancer detection products are also sold through OEM partners, including GE Healthcare, Fuji Medical Systems, Siemens Medical, Vital Images and Invivo. For the year ended December 31, 2017, these five OEM partners composed approximately 55% of Detection revenues and 39% of revenue overall. OEM partners composed 47% of Detection revenues and 30% of revenue overall for the year ended December 31, 2016 and 53% of Detection revenues and 25% of revenue overall for the year ended December 31, 2015. OEM partners represented $3.7 million or 43% of outstanding receivables as of December 31, 2017, with GE Healthcare accounting for $2.9 million or 34% of this amount. The two largest Cancer Therapy customers composed $0.9 million or 11% of outstanding receivables as of December 31, 2017. These seven customers in total represented $4.6 million or 54% of outstanding receivables as of December 31, 2017.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(9) Commitments and Contingencies (a) Lease Obligations As of December 31, 2017, the Company had three lease obligations related to its facilities. The Company’s executive offices are leased pursuant to a five-year lease (the “Lease”) that commenced on December 15, 2006, with renewals in January, 2012 and August 2016 of office space located at 98 Spit Brook Road, Suite 100 in Nashua, New Hampshire (the “Premises”). The August 2016 Lease renewal provides for an annual base rent of $184,518 for the period from March 2017 to February 2020. Additionally, the Company is required to pay its proportionate share of the building and real estate tax expenses and obtain insurance for the Premises. The Company leases a facility in San Jose California under a non-cancelable operating lease which commenced in September 2012. The operating lease commenced September 2012 with a current annual payment of $295,140 through September 2017, with all amounts payable in equal monthly installments. In September 2016, the Company extended this lease for the period from October 2017 to March 2020 with annual payments of $540,588 from October 2017 to September 2018, $558,120 from October 2018 to September 2019 and $286,368 for the period from October 2019 to March 2020, with all amounts payable in equal monthly installments. Additionally, the Company is required to pay its proportionate share of the building and real estate tax expenses and obtain insurance for the facility. In addition to the foregoing leases relating to its principal properties, the Company also has a lease for an additional facility in Nashua, New Hampshire used for product repairs, manufacturing and warehousing. Rent expense for all leases for the years ended December 31, 2017, 2016 and 2015 was $899,000, $745,000 and $663,000, respectively. Future minimum rental payments due under these agreements as of December 31, 2016 are as follows (in thousands): Fiscal Year Operating Leases 2018 $ 764 2019 755 2020 174 $ 1,693 (b) Capital lease obligations In August, 2017, the Company assumed an equipment lease obligation with payments totaling $50,000. The leases were determined to be capital leases and accordingly the equipment was capitalized and a liability of $42,000 was recorded. The equipment will be depreciated over the expected life of 3 years. The remaining minimum lease payments are as follows (in thousands): Fiscal Year Capital Lease 2018 $ 17 2019 17 2020 13 subtotal minimum lease obligation 47 less interest (8 ) Total, net 39 less current portion (12 ) long term portion $ 27 (c) Other Commitments The Company has non-cancelable purchase orders with three key suppliers executed in the normal course of business that total approximately $0.3 million. In connection with the Company’s employee savings plans, the matching contribution for 2017 was approximately $0.5 million in cash. The matching contribution for 2018 is estimated to be approximately $0.5 million in cash. (d) Employment Agreements The Company has entered into employment agreements with certain key executives. The employment agreements provide for minimum annual salaries and performance-based annual bonus compensation as defined in their respective agreements. In addition, the employment agreements provide that if employment is terminated without cause, the executive will receive an amount equal to their respective base salary then in effect for the greater of the remainder of the original term of employment or, for Mr. Ferry, a period of two years from the date of termination, for Mr. Christopher and Ms. Stevens, a period of eighteen months from the date of termination, in each case, plus the pro rata portion of any annual bonus earned in any employment year through the date of termination. (e) Foreign Tax Claim In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment of approximately $6,800,000 from the Canada Revenue Agency (“CRA”) resulting from CRA’s audit of CADx Medical’s Canadian federal tax return for the year ended December 31, 2002. In February 2010, the CRA reviewed the matter and reduced the tax re-assessment to approximately $703,000, excluding interest and penalties. The CRA has the right to pursue the matter until July 2020. The Company believes that it is not liable for the re-assessment against CADx Medical and continues to defend this position. As the Company believes that a probability of a loss is remote, no accrual was recorded as of December 31, 2017. (f) Royalty Obligations In connection with prior litigation, the Company received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete covenant as well as an agreement not to seek further damages with respect to the alleged patent violations. In return the Company had a remaining obligation to pay a minimum annual royalty payment of $250,000 payable through 2016. In addition to the minimum annual royalty payments, the litigation settlement agreement with Hologic also provides for payment of royalties if such royalties exceed the minimum payment based upon a specified percentage of future net sales on any products that practice the licensed rights. The estimated fair value of the patent license and non-compete covenant is $100,000 and is being amortized over the estimated remaining useful life of approximately four years. In addition, a liability has been recorded within accrued expenses and accounts payable for future payment and for minimum royalty obligations totaling $0.4 million. During December 2011, the Company settled litigation with Zeiss with a final payment of pay $0.5 million which was paid in June 2017. (g) Litigation The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should we fail to prevail in any legal matter or should several legal matters be resolved against us in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Quarterly Financial Data

Quarterly Financial Data	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	(10) Quarterly Financial Data Net Gross Net loss Income (loss) Weighted 2017 First quarter $ 6,791 $ 4,689 $ (457 ) ($ 0.03 ) 16,135 Second quarter 6,409 4,503 $ (2,631 ) ($ 0.16 ) 16,310 Third quarter 7,000 4,643 $ (6,933 ) ($ 0.42 ) 16,424 Fourth quarter 7,902 4,341 $ (4,235 ) ($ 0.26 ) 16,501 2016 First quarter $ 6,038 $ 4,186 $ (2,533 ) ($ 0.16 ) 15,826 Second quarter 7,369 5,702 $ (1,575 ) ($ 0.10 ) 15,904 Third quarter 6,003 4,101 $ (2,675 ) ($ 0.17 ) 15,957 Fourth quarter 6,928 4,529 $ (3,316 ) ($ 0.21 ) 16,042

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Nature of Operations and Use of Estimates	(a) Nature of Operations and Use of Estimates iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company has grown primarily through acquisitions to become a broad player in the oncology market. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, MRI and CT, and the Xoft System which is an isotope-free cancer treatment platform technology. CAD is reimbursable in the U.S. under federal and most third-party insurance programs. The Company intends to continue the extension of its image analysis and clinical decision support solutions for mammography, MRI and CT imaging. iCAD believes that advances in digital imaging techniques should bolster its efforts to develop additional commercially viable CAD/advanced image analysis and workflow products. The Company’s management believes that early detection in combination with earlier targeted intervention will provide patients and care providers with the best tools available to achieve better clinical outcomes resulting in a market demand that will drive top line growth. The Company’s headquarters are located in Nashua, New Hampshire, with manufacturing and contract manufacturing facilities in New Hampshire and Massachusetts, and an operations, research, development, manufacturing and warehousing facility in San Jose, California. The Company operates in two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products, and the Therapy segment consists of radiation therapy products. The Company sells its products throughout the world through its direct sales organization as well as through various OEM partners, distributors and resellers. See Note 8 for segment, major customer and geographical information. The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. In January 2018 the Company adopted a plan to discontinue offering radiation therapy professional services to practices that provide the Company’s electronic brachytherapy solution for the treatment of non-melanoma
Principles of Consolidation	(b) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xoft, Inc. and Xoft Solutions, LLC. All material inter-company transactions and balances have been eliminated in consolidation.
Cash and cash equivalents	(c) Cash and cash equivalents The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 days or less, which are unrestricted as to withdrawal. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage is $250,000 per depositor at each financial institution, and the Company’s non-interest
Financial instruments	(d) Financial instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable. Due to their short term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2017 and 2016.
Accounts Receivable and Allowance for Doubtful Accounts	(e) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are customer obligations due under normal trade terms. Credit limits are established through a process of reviewing the financial history and stability of each customer. The Company performs continuing credit evaluations of its customers’ financial condition and generally does not require collateral. The Company’s policy is to maintain allowances for estimated losses from the inability of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may potentially be uncollectible. The Company includes any accounts receivable balances that it determines may likely be uncollectible, along with a general reserve for estimated probable losses based on historical experience, in its overall allowance for doubtful accounts. An amount would be written off against the allowance after all attempts to collect the receivable had failed. Based on the information available, the Company believes the allowance for doubtful accounts as of December 31, 2017 and 2016 is adequate. The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2017 (in thousands): 2017 2016 2015 Balance at beginning of period $ 172 $ 236 $ 203 Additions charged to costs and expenses 45 177 383 Reductions (110 ) (241 ) (350 ) Balance at end of period $ 107 $ 172 $ 236
Inventory	(f) Inventory Inventory is valued at the lower of cost or net realizable value, with cost determined by the first-in, first-out As of December 31, 2017 2016 Raw materials $ 992 $ 2,503 Work in process 63 75 Finished Goods 1,068 1,149 Inventory $ 2,123 $ 3,727
Property and Equipment	(g) Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, if shorter, for leasehold improvements (see below). Estimated life Equipment 3-5 Leasehold improvements 3-5 Furniture and fixtures 3-5 Marketing assets 3-5
Goodwill	(h) Goodwill In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350-20, “Intangibles—Goodwill and Other” 350-20”), Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company records an impairment charge when such assessment indicates that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of reporting units. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. In January 2018 the Company adopted a plan to discontinue offering radiation therapy professional services to practices that provide the Company’s electronic brachytherapy solution for the treatment of non-melanoma The Company elected to early adopt ASU 2017-04, 2017-04”) 2017-04 As a result of the underperformance of the Therapy reporting unit as compared to expected future results, the Company determined there was a triggering event in the third quarter of 2017. As a result, the Company completed an interim impairment assessment. The interim test resulted in the fair value of the Therapy reporting unit being less than the carrying value of the reporting unit. The fair value of the Therapy reporting unit was $3.5 million and the carrying value was $7.5 million. The deficiency of $4.0 million was recorded as an impairment charge in the third quarter ended September 30, 2017. The Company did not identify a triggering event within the Detection reporting unit and accordingly did not perform an interim test. As a result of external factors and general uncertainty related to reimbursement for non-melanoma The Company determines the fair value of reporting units based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. This approach was selected as it measures the income producing assets, primarily technology and customer relationships. This method estimates the fair value based upon the ability to generate future cash flows, which is particularly applicable when future profit margins and growth are expected to vary significantly from historical operating results. The Company uses internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for the reporting unit. Accordingly, actual results can differ from those assumed in the forecasts. Discount rates are derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting unit to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts. Other significant assumptions include terminal value margin rates, future capital expenditures, and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to the application of these assumptions to this analysis, the income approach provides a reasonable estimate of the fair value of the Therapy reporting unit. The Company performed the annual impairment assessment at October 1, 2017 and compared the fair value of each of reporting unit to its carrying value as of this date. Fair value exceeded the carrying value for the Detection reporting unit, and the carrying value approximated fair value of the Therapy reporting unit after the impairment as of September 30, 2017. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities, to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment. The Company determines the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on our most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in our forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weights the methodologies appropriately. In April 2015, the Company acquired VuComp’s M-Vu ® In January 2016, the Company completed the acquisition of VuComp’s M-Vu In December 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. The Company conveyed to Buyer all right, title and interest to certain intellectual property relating to the VersaVue Software and the DynaCAD product and related assets. As a result of the agreement, the Company determined that it had assets held for sale as of December 31, 2016 and the sale constituted the sale of a business. As of December 31, 2016, the Company allocated $394,000 of goodwill to assets held for sale. The allocation was based on the fair value of the assets sold relative to the fair value of the Detection reporting unit as of the date of the agreement. A rollforward of goodwill activity by reportable segment is as follows (in thousands): Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at December 31, 2015 8,463 5,735 14,198 Acquisition of VuComp 293 — 293 Sale of MRI assets (394 ) — (394 ) Balance at December 31, 2016 8,362 5,735 14,097 Impairment — (5,735 ) (5,735 ) Balance at December 31, 2017 $ 8,362 $ — $ 8,362 Accumulated Goodwill 699 6,270 54,906 Fair value allocation 7,663 13,446 — Accumulated impairment — (19,716 ) (46,544 ) Balance at December 31, 2017 $ 8,362 $ — $ 8,362
Long Lived Assets	(i) Long Lived Assets In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360-10-35 360-10-35-21, • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). In accordance with ASC 360-10-35-17, The Company completed an interim goodwill impairment assessment for the Therapy reporting unit in the third quarter of 2017 and noted that there was an impairment of goodwill. As a result, the Company determined this was a triggering event to review long-lived assets for impairment. Accordingly, the Company completed an analysis pursuant to ASC 360-10-35-17 The Company also completed a goodwill assessment in the fourth quarter of 2017, and in connection with that assessment, the Company completed an analysis pursuant to ASC 360-10-35-17 The Company did not record any impairment charges for the year ended December 31, 2016. As a result of external factors and general uncertainty related to reimbursement for the treatment of NMSC, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for impairment in 2015. In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the Asset Group. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values, and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges. Intangible assets subject to amortization consist primarily of patents, technology, customer relationships and trade names purchased in the Company’s previous acquisitions. These assets, which include assets from the acquisition of the assets of VuComp, DermEbx and Radion and the acquisition of Xoft, Inc., are amortized on a straight-line basis consistent with the pattern of economic benefit over their estimated useful lives of 5 to 15 years. A summary of intangible assets for 2017 and 2016 are as follows (in thousands): 2017 2016 Weighted Gross Carrying Amount Patents and licenses $ 556 $ 583 5 years Technology 8,257 9,567 10 years Customer relationships 292 292 7 years Tradename 259 259 10 years Total amortizable intangible assets 9,364 10,701 Accumulated Amortization Patents and licenses $ 503 $ 477 Technology 6,610 6,754 Customer relationships 61 28 Tradename 259 259 Total accumulated amortization 7,433 7,518 Total amortizable intangible assets, net $ 1,931 $ 3,183 Amortization expense related to intangible assets was approximately $494,000, $983,000 and $1,768,000 for the years ended December 31, 2017, 2016, and 2015, respectively. Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): For the years ended December 31: Estimated 2018 $ 417 2019 379 2020 305 2021 228 2022 299 Thereafter 303 $ 1,931
Revenue Recognition	(j) Revenue Recognition The Company recognizes revenue primarily from the sale of products, services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement. The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, Multiple-Deliverable Revenue Arrangement 2009-13”) No. 2009-14, Certain Arrangements That Contain Software Elements 2009-14”) 985-605, “Software” 985-605”). Leases” The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references. If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process. The Company has determined that iCAD’s digital and film based sales generally follow the guidance of FASB ASC Topic 605 “ Revenue Recognition 2009-14. 2009-13. Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, Services
Cost of Revenue	(k) Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house
Warranty Costs	(l) Warranty Costs The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including the cost of product returns during the warranty period. Warranty provisions and claims for the years ended December 31, 2017, 2016 and 2015, were as follows (in thousands): 2017 2016 2015 Beginning accrual balance $ 11 $ 19 $ 14 Warranty provision 49 47 54 Usage (50 ) (55 ) (49 ) Ending accrual balance $ 10 $ 11 $ 19 The warranty accrual above includes long-term warranty obligations of $0, $0 and $2,000 for the years ended December 31, 2017, 2016 and 2015 respectively.
Engineering and Product Development Costs	(m) Engineering and Product Development Costs Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials which are expensed as incurred.
Advertising Costs	(n) Advertising Costs The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2017, 2016 and 2015 was approximately $990,000, $955,000 and $950,000 respectively.
Net Loss per Common Share	(o) Net Loss per Common Share The Company follows FASB ASC 260-10, A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2017 2016 2015 Net loss available to common shareholders $ (14,256 ) $ (10,099 ) $ (32,447 ) Basic shares used in the calculation of earnings per share 16,343 15,932 15,686 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 16,343 15,932 15,686 Net loss per share : Basic $ (0.87 ) $ (0.63 ) $ (2.07 ) Diluted $ (0.87 ) $ (0.63 ) $ (2.07 ) The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive: 2017 2016 2015 Common stock options 1,465,115 1,425,348 1,571,998 Restricted Stock 415,147 511,398 516,396 1,880,262 1,936,746 2,088,394 Restricted common stock can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares were excluded from the computation of basic loss per share as these shares are not considered outstanding until vested.
Income Taxes	(p) Income Taxes The Company follows the liability method under ASC Topic 740, “Income Taxes”, (“ASC 740”). The primary objectives of accounting for taxes under ASC 740 are to (a) recognize the amount of tax payable for the current year and (b) recognize the amount of deferred tax liability or asset for the future tax consequences of events that have been reflected in the Company’s financial statements or tax returns. The Company has provided a full valuation allowance against its deferred tax assets at December 31, 2017 and 2016, as it is more likely than not that the deferred tax asset will not be realized. Any subsequent changes in the valuation allowance will be recorded through operations in the provision (benefit) for income taxes. ASC 740-10 740-10 de-recognition,
Stock-Based Compensation	(q) Stock-Based Compensation The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company may grant to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may grant restricted stock to employees and directors. The underlying shares of the restricted stock grant are not issued until the shares vest, and compensation expense is based on the stock price of the shares at the time of grant. The Company follows FASB ASC Topic 718, “Compensation – Stock Compensation” (“ASC 718”), for all stock-based compensation. Under this application, the Company is required to record compensation expense over the vesting period for all awards granted. The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, the risk free rate, expected dividend yield, and the number of options that will be forfeited prior to the completion of their vesting requirements. The fair value of restricted stock is determined based on the stock price of the underlying option on the date of the grant. The Company granted performance based restricted stock during 2016 based on achievement of certain revenue targets. Compensation cost for performance based restricted stock requires significant judgment regarding probability of the performance objectives and compensation cost is re-measured Application of alternative assumptions could produce significantly different estimates of the fair value of stock-based compensation and consequently, the related amounts recognized in the Consolidated Statements of Operations.
Fair Value Measurements	(r) Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurement and Disclosures” (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The money market funds are included in cash and cash equivalents in the accompanying balance sheet, and are considered a level 1 investment as they are valued at quoted market prices in active markets. The following table sets forth Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2017 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 8,853 $ — $ — $ 8,853 Total Assets $ 8,853 $ — $ — $ 8,853 Fair value measurements using: (000’s) as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,622 $ — $ — $ 6,622 Total Assets $ 6,622 $ — $ — $ 6,622 Items Measured at Fair Value on a Nonrecurring Basis Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. In 2015 the Company recorded a $27.4 million impairment consisting of $14.0 million related to goodwill and $13.4 million related to long-lived assets as discussed in Note (h) and Note (i) and re-measured
Recently Issued and Recently Adopted Accounting Standards	(s) Recently Issued and Recently Adopted Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, 2014-09, 2016-08, 2016-10, No. 2014-09. 2014-09 one-year The Company has performed an assessment of its revenue streams and customer classes. During the fourth quarter of 2017, the Company completed its implementation plan and finalized contract reviews and detailed policy drafting. The Company will adopt the guidance effective January 1, 2018 using the modified retrospective approach, by recognizing the cumulative effect of initially applying the new standard as an increase to the opening balance of retained earnings. We expect this adjustment to be less than $0.1 million and do not expect a material impact on our revenue recognition practices on an ongoing basis. The Company will adopt certain practical expedients and make certain policy elections related to the accounting for significant finance components, sales taxes, shipping and handling, costs to obtain a contract, and immaterial promised goods or services, which will mitigate certain impacts of adopting Topic 606. The immaterial impact of adopting Topic 606 primarily relates to (a) the deferral of commissions on our long-term service arrangements and warranty periods greater than one year, which previously were expensed as incurred but under the amendments to ASC 340-40 Leases non-lease The impact to our results is not material because the analysis of our contracts under the new revenue recognition standard supports the recognition of revenue at a point in time for product sales and over time for service contracts (as well as for the lease components of certain CAD products), which is consistent with our current revenue recognition model. A significant portion of our revenue is generated from sales of cancer detection products and cancer therapy systems, and revenue is recognized when delivery has occurred as our performance obligation would be complete. The revenue components that are not primarily associated with the sale of these products, such as physics and management services, development fees, and supplies, are also not expected to be materially impacted by the adoption of the new standard. For performance obligations where the transfer of control occurs over-time, a time-based measure of progress (e.g., straight-line) continues to best depict the transfer of control of services to the customer for fixed fee service contracts and source agreements that represent stand-ready obligations to make goods or services available for the customer to use as and when the customer decides. For professional service contracts entered into with customers on a time and materials basis, an input-based measure of progress based on the number of days incurred or hours expended continues to best depict our progress toward complete satisfaction of the performance obligation. In addition, the number of our performance obligations under the new standard is not materially different from our contract deliverables under the existing standard. Lastly, the accounting for the estimate of variable consideration is not materially different compared to our current practice. We also do not expect the standard to have a material impact on our consolidated balance sheet. The immaterial impact primarily relates to capitalization of commissions on our long-term service arrangements and warranty periods greater than one year and reclassifications among financial statement accounts to align with the new standard. Most notably, capitalized commissions will be classified as deferred contract costs and advance payments and deferred revenue will be combined and reclassified as contract liabilities. Our contract balances will be reported in a net contract asset or liability position on a contract-by-contract Adoption of the standard would result in an increase in other current and long-term assets of approximately $0.1 million as of December 31, 2017, driven by capitalization of commissions on our long-term service arrangements and warranty periods greater than one year, as well as the reclassification of approximately $0.4 million in deferred revenue as of December 31, 2017 related to the lease components of certain CAD products which are outside the scope of Topic 606 to accrued expenses. There are also certain considerations related to internal control over financial reporting that are associated with implementing Topic 606. The Company is currently evaluating its internal control framework over revenue recognition and making adjustments to the framework to enable the preparation of financial information and to obtain and disclose the information required under Topic 606. This evaluation is not expected to result in any material changes to the Company’s existing internal control framework over revenue recognition. In February 2016, the FASB issued ASU No. 2016-02, right-of-use off-balance On January 1, 2017, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-09, 2016-09”), 2016-09, In August 2016, the FASB issued ASU 2016-15, In November 2016, the FASB issued Accounting Standards Update No. 2016-18, non-restricted 2016-18 In February 2017, the FASB issued ASU 2017-04,
Segment Reporting	In accordance with FASB Topic ASC 280, “ Segments
Litigation	Litigation The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should we fail to prevail in any legal matter or should several legal matters be resolved against us in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Allowance for Doubtful Accounts	The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2017 (in thousands): 2017 2016 2015 Balance at beginning of period $ 172 $ 236 $ 203 Additions charged to costs and expenses 45 177 383 Reductions (110 ) (241 ) (350 ) Balance at end of period $ 107 $ 172 $ 236
Schedule of Current Inventory	At December 31, 2017 and 2016, inventories consisted of the following (in thousands), which includes an inventory reserve of approximately $1.2 million and $0.3 million as December 31, 2017 and 2016, respectively. As of December 31, 2017 2016 Raw materials $ 992 $ 2,503 Work in process 63 75 Finished Goods 1,068 1,149 Inventory $ 2,123 $ 3,727
Schedule of Property and Equipment Estimated Useful Lives	Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, if shorter, for leasehold improvements (see below). Estimated life Equipment 3-5 Leasehold improvements 3-5 Furniture and fixtures 3-5 Marketing assets 3-5
Roll Forward of Goodwill Activity by Reportable Segment	A rollforward of goodwill activity by reportable segment is as follows (in thousands): Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at December 31, 2015 8,463 5,735 14,198 Acquisition of VuComp 293 — 293 Sale of MRI assets (394 ) — (394 ) Balance at December 31, 2016 8,362 5,735 14,097 Impairment — (5,735 ) (5,735 ) Balance at December 31, 2017 $ 8,362 $ — $ 8,362 Accumulated Goodwill 699 6,270 54,906 Fair value allocation 7,663 13,446 — Accumulated impairment — (19,716 ) (46,544 ) Balance at December 31, 2017 $ 8,362 $ — $ 8,362
Schedule of Intangible Assets	A summary of intangible assets for 2017 and 2016 are as follows (in thousands): 2017 2016 Weighted Gross Carrying Amount Patents and licenses $ 556 $ 583 5 years Technology 8,257 9,567 10 years Customer relationships 292 292 7 years Tradename 259 259 10 years Total amortizable intangible assets 9,364 10,701 Accumulated Amortization Patents and licenses $ 503 $ 477 Technology 6,610 6,754 Customer relationships 61 28 Tradename 259 259 Total accumulated amortization 7,433 7,518 Total amortizable intangible assets, net $ 1,931 $ 3,183
Schedule of Expected Amortization Expense	Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): For the years ended December 31: Estimated 2018 $ 417 2019 379 2020 305 2021 228 2022 299 Thereafter 303 $ 1,931
Roll forward of Warranty Cost	Warranty provisions and claims for the years ended December 31, 2017, 2016 and 2015, were as follows (in thousands): 2017 2016 2015 Beginning accrual balance $ 11 $ 19 $ 14 Warranty provision 49 47 54 Usage (50 ) (55 ) (49 ) Ending accrual balance $ 10 $ 11 $ 19
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2017 2016 2015 Net loss available to common shareholders $ (14,256 ) $ (10,099 ) $ (32,447 ) Basic shares used in the calculation of earnings per share 16,343 15,932 15,686 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 16,343 15,932 15,686 Net loss per share : Basic $ (0.87 ) $ (0.63 ) $ (2.07 ) Diluted $ (0.87 ) $ (0.63 ) $ (2.07 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive: 2017 2016 2015 Common stock options 1,465,115 1,425,348 1,571,998 Restricted Stock 415,147 511,398 516,396 1,880,262 1,936,746 2,088,394
Assets which are Measured at Fair Value on a Recurring Basis	The following table sets forth Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2017 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 8,853 $ — $ — $ 8,853 Total Assets $ 8,853 $ — $ — $ 8,853 Fair value measurements using: (000’s) as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,622 $ — $ — $ 6,622 Total Assets $ 6,622 $ — $ — $ 6,622

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2017
MVu Breast Density [Member]
Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	As a result the Company recorded a gain on litigation settlement of $249,000 in the first quarter of 2016, which is a component of the purchase price as noted below: Amount (000’s) Cash $ 6 Acquisition litigation settlement 249 Purchase price $ 255
VuComp Cancer Detection Portfolio [Member]
Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following is a summary of the allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life: Amount (000’s) Estimated Current assets $ 84 Property and equipment 65 3 Years Identifiable intangible assets 699 1-10 Years Goodwill 293 Current liabilities (280 ) Long-term liabilities (606 ) Purchase price $ 255
VuComp M-Vu Breast Density Product [Member]
Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following is a summary of the allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life (in thousands): Amount Estimated Amortizable Developed Technology $ 900 8 years 9 months Goodwill 800 Purchase price $ 1,700

Sale of MRI Assets (Tables)

Sale of MRI Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Net Assets Sold	The value of the net assets sold is as follows (in thousands): Assets Accounts Receivable $ 116 Intangible assets 810 Allocated Goodwill 394 Total Assets $ 1,320 Liabilities Deferred Revenue $ 746 Total Liabilities $ 746 Net Assets Sold $ 574
Schedule of Components of Gain on Sale	2017. The components of the gain on the sale are as follows (in thousands): Gain on Sale Cash received $ 2,850 Holdback reserve 350 Fair value of transition services (118 ) Net Assets sold (574 ) Total $ 2,508

Financing Arrangements (Tables)

Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Carrying Value of Term Loan Net of Debt Issuance Costs	The carrying value of the Term Loan (net of debt issuance costs) as of December 31, 2017 is as follows (in thousands): December 31, 2017 Principal Amount of Term Loan $ 6,000 Unamortized closing costs (64 ) Carrying amount of Term Loan 5,936 Less current portion of Term Loan (817 ) Notes payable long-term portion $ 5,119
Summary of Principal and Interest Payments	Principal and interest payments are as follows (in thousands): Fiscal Year Amount Due 2018 $ 1,086 2019 $ 2,183 2020 $ 2,097 2021 $ 1,183 Total $ 6,549
Interest Expense in Consolidated Income Statement	The following amounts are included in interest expense in our consolidated statement of operations for the years ended December 31, 2017, 2016 and 2015 (in thousands): December 31, 2017 December 31, 2016 December 31, 2015 Cash interest expense $ 98 $ — $ 163 Non-cash $ — $ — $ 254 Amortization of debt costs 9 — 13 Amortization of settlement obligations 26 82 146 Interest expense capital lease 1 70 220 Capital lease—fair value amortization (10 ) (89 ) (146 ) Total interest expense $ 124 $ 63 $ 650

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consist of the following at December 31 (in thousands): 2017 2016 Accrued salary and related expenses $ 1,388 $ 1,878 Accrued accounts payable 2,523 2,269 Accrued professional fees 418 316 Accrued short term settlement costs — 474 Other accrued expenses 70 48 Deferred rent 76 3 $ 4,475 $ 4,988

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Stock Option Activity for all Stock Option Plans	A summary of stock option activity for all stock option plans is as follows: Number of Weighted Average Weighted Average Outstanding, January 1, 2015 1,417,887 $ 4.34 Granted 363,239 $ 6.58 Exercised (79,472 ) $ 4.60 Forfeited (129,656 ) $ 7.38 Outstanding, December 31, 2015 1,571,998 $ 5.05 Granted 127,500 $ 5.46 Exercised (75,583 ) $ 2.62 Forfeited (198,567 ) $ 6.19 Outstanding, December 31, 2016 1,425,348 $ 5.05 Granted 200,813 $ 4.14 Exercised (36,530 ) $ 2.18 Forfeited (124,516 ) $ 4.71 Outstanding, December 31, 2017 1,465,115 $ 5.03 5.3 years Exercisable at December 31, 2015 1,087,725 $ 4.33 Exercisable at December 31, 2016 1,054,211 $ 4.71 Exercisable at December 31, 2017 1,301,651 $ 4.95 5.0 years
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Years Ended December 31, 2017 2016 2015 Cost of revenue $ 5 $ 6 $ 14 Engineering and product development 715 329 223 Marketing and sales 1,003 677 659 General and administrative expense 1,933 1,295 1,239 $ 3,656 $ 2,307 $ 2,135
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Years Ended December 31, 2017 2016 2015 Average risk-free interest rate 1.61 % 0.98 % 0.97 % Expected dividend yield None None None Expected life 3.5 years 3.5 years 3.5 years Expected volatility 64.2% to 72.0 % 68.5% to 75.3 % 60.5% to 75.2 % Weighted average exercise price $ 4.14 $ 5.46 $ 6.58 Weighted average fair value $ 1.99 $ 2.66 $ 3.17
Summary of Intrinsic Values of Options and Closing Market Price	Intrinsic values of options (in thousands) and the closing market price used to determine the intrinsic values are as follows: Years Ended December 31, 2017 2016 2015 Outstanding $ 449 $ 409 $ 1,910 Exercisable 442 409 1,610 Exercised 79 201 317 stock price at 12/31 $ 3.44 $ 3.24 $ 5.17
Summary of Restricted Stock Activity for All Equity Incentive Plans	A summary of restricted stock activity for all equity incentive plans is as follows: Years Ended December 31, 2017 2016 2015 Beginning outstanding balance 511,398 516,396 309,317 Granted 394,599 345,778 352,666 Vested (469,434 ) (289,030 ) (124,758 ) Forfeited (21,416 ) (61,746 ) (20,829 ) Ending outstanding balance 415,147 511,398 516,396
Summary of Intrinsic Values of Restricted Stock and Closing Market Price	Intrinsic values of restricted stock (in thousands) and the closing market price used to determine the intrinsic values are as follows: Years Ended December 31, 2017 2016 2015 Outstanding $ 1,428 $ 1,657 $ 2,670 Vested 1,615 936 645 stock price at 12/31 $ 3.44 $ 3.24 $ 5.17

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Components of Income Tax Expense	The components of income tax expense for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): 2017 2016 2015 Current provision (benefit): Federal $ — $ — $ — State (26 ) 69 95 $ (26 ) $ 69 $ 95 Deferred provision: Federal $ 7 $ 6 $ (65 ) State 1 1 (14 ) $ 8 $ 7 $ (79 ) Total $ (18 ) $ 76 $ 16
Summary of Effective and the Federal Statutory Income Tax Rate	A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31, 2017, 2016 and 2015 is as follows: 2017 2016 2015 Federal statutory rate 34.0 % 34.0 % 34.0 % State income taxes, net of federal benefit 1.4 % 2.8 % 2.5 % Net state impact of deferred rate change (0.3 %) 0.2 % (0.1 %) Stock compensation expense (1.9 %) (3.2 %) (0.7 %) Tax amortization on goodwill (0.1 %) (0.1 %) 0.2 % Goodwill impairment (13.7 %) 0.0 % (10.0 %) Other permanent differences (0.4 %) (0.4 %) (0.1 %) Change in valuation allowance 97.4 % (37.3 %) (26.6 %) Tax credits 1.5 % 3.2 % 0.9 % Federal Rate Change (133.5 %) 0.0 % 0.0 % Accrual to TR (0.7 %) 0.0 % 0.0 % Increase Xoft NOLs under 382 Study 16.2 % 0.0 % 0.0 % Effective income tax (0.10 %) (0.8 %) 0.1 %
Deferred Tax Assets (Liabilities)	Deferred tax assets (liabilities) are composed of the following at December 31 (in thousands): 2017 2016 Inventory (Section 263A) $ 287 $ 418 Inventory reserves 305 105 Receivable reserves 27 65 Other accruals 224 434 Deferred revenue 129 215 Accumulated depreciation/amortization 320 477 Stock options 1,901 2,558 Developed technology 2,201 3,594 Tax credits 3,130 3,090 NOL carryforward 31,113 40,865 Net deferred tax assets 39,637 51,821 Valuation allowance (39,637 ) (51,821 ) Goodwill tax amortization (14 ) (7 ) Deferred tax liability $ (14 ) $ (7 )

Segment Reporting, Geographic26

Segment Reporting, Geographical Information and Major Customers (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands, including prior periods which have been presented for consistency): Year Ended December 31, 2017 2016 2015 Segment revenues: Detection $ 18,310 $ 17,133 $ 19,243 Therapy 9,792 9,205 22,311 Total Revenue $ 28,102 $ 26,338 $ 41,554 Segment gross profit: Detection $ 16,218 $ 15,113 $ 16,019 Therapy 1,958 3,405 13,331 Segment gross profit $ 18,176 $ 18,518 $ 29,350 Segment operating income (loss): Detection $ 6,401 $ 5,694 $ 7,233 Therapy (15,102 ) (7,752 ) (28,405 ) Segment operating income (loss) $ (8,701 ) $ (2,058 ) $ (21,172 ) General, administrative, depreciation and amortization expense $ (7,975 ) $ (7,912 ) $ (8,907 ) Interest expense (124 ) (63 ) (650 ) Gain on sale of MRI assets 2,508 — — Other income 18 10 21 Loss on debt extinguishment — — (1,723 ) Loss before income tax $ (14,274 ) $ (10,023 ) $ (32,431 )
Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss)	Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands): Detection depreciation and amortization Depreciation $ 172 $ 223 $ 220 Amortization 246 696 532 Therapy depreciation and amortization Depreciation $ 768 $ 970 $ 1,142 Amortization 222 252 1,213

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Rental Payments	Future minimum rental payments due under these agreements as of December 31, 2016 are as follows (in thousands): Fiscal Year Operating Leases 2018 $ 764 2019 755 2020 174 $ 1,693
Future Minimum Lease Payments under Non-cancelable Capital Leases	The remaining minimum lease payments are as follows (in thousands): Fiscal Year Capital Lease 2018 $ 17 2019 17 2020 13 subtotal minimum lease obligation 47 less interest (8 ) Total, net 39 less current portion (12 ) long term portion $ 27

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	Net Gross Net loss Income (loss) Weighted 2017 First quarter $ 6,791 $ 4,689 $ (457 ) ($ 0.03 ) 16,135 Second quarter 6,409 4,503 $ (2,631 ) ($ 0.16 ) 16,310 Third quarter 7,000 4,643 $ (6,933 ) ($ 0.42 ) 16,424 Fourth quarter 7,902 4,341 $ (4,235 ) ($ 0.26 ) 16,501 2016 First quarter $ 6,038 $ 4,186 $ (2,533 ) ($ 0.16 ) 15,826 Second quarter 7,369 5,702 $ (1,575 ) ($ 0.10 ) 15,904 Third quarter 6,003 4,101 $ (2,675 ) ($ 0.17 ) 15,957 Fourth quarter 6,928 4,529 $ (3,316 ) ($ 0.21 ) 16,042

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Additional Information (Detail)	Jan. 13, 2016USD ($)	Apr. 29, 2015USD ($)	Jan. 31, 2016USD ($)	Apr. 30, 2015USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2017USD ($)Segment	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business segment | Segment								2
Maturity for cash and cash equivalents								90 days
Insurance coverage								$ 250,000
Interest-bearing amounts on deposit in excess of federally					$ 8,500,000			8,500,000
Inventory reserve					1,200,000			1,200,000	$ 300,000
Goodwill					8,362,000			8,362,000	14,097,000	$ 14,198,000
Goodwill impairment loss								5,735,000		13,981,000
Allocation of goodwill to asset held for sale									394,000
Impairment charges on long lived assets										13,400,000
Carrying value of asset group					576,000			576,000	1,385,000
Asset impairment charges								6,693,000	0	27,443,000
Amortization expense related to intangible assets								494,000	983,000	1,768,000
Medical Device Excise tax included in the cost of revenue									491,000
Long term warranty obligations								0	0	2,000
Advertising expense								990,000	955,000	950,000
Impairment charges on long-lived and other assets								1,000,000
Deferred tax asset, net operating loss					31,113,000			31,113,000	40,865,000
Accounting Standards Update 2014-09 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Increase in other long-term assets					100,000			100,000
Deferred revenue reclassified					400,000			400,000
ASU 2016-09 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Deferred tax asset, net operating loss					1,900,000			1,900,000
Detection [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Goodwill					8,362,000			8,362,000	8,362,000	8,463,000
Amortization expense related to intangible assets								246,000	696,000	532,000
Therapy [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Fair value of goodwill							$ 5,700,000
Goodwill									5,735,000	5,735,000
Goodwill impairment loss							14,000,000	5,735,000		13,981,000
Impairment charges on long lived assets						$ 700,000	13,400,000
Carrying value of asset group							36,800,000
Undiscounted cash flows over carrying value of assets							$ 2,800,000
Amortization expense related to intangible assets								222,000	252,000	1,213,000
Therapy [Member] | ASU 2017-04 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Fair value of goodwill					100,000	7,500,000		100,000
Goodwill					2,100,000	7,500,000		$ 2,100,000
Goodwill impairment loss					$ 1,700,000	$ 4,000,000
MVu Breast Density [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business acquisition paid in cash	$ 6,000		$ 6,000
VuComp M-Vu CAD [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business acquisition paid in cash									$ 6,000
VuComp M-Vu CAD [Member] | Detection [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Goodwill			$ 293,000
VuComp M-Vu Breast Density Product [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Goodwill		$ 800,000
Business acquisition paid in cash		$ 1,700,000		$ 1,700,000						$ 1,700,000
Estimated useful lives of Long-lived assets		8 years 9 months
VuComp M-Vu Breast Density Product [Member] | Detection [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Goodwill				$ 800,000
Minimum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets								5 years
Maximum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets								15 years

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Balance at beginning of period	$ 172	$ 236	$ 203
Additions charged to costs and expenses	45	177	383
Reductions	(110)	(241)	(350)
Balance at end of period	$ 107	$ 172	$ 236

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 992	$ 2,503
Work in process	63	75
Finished Goods	1,068	1,149
Inventory	$ 2,123	$ 3,727

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] | Marketing Assets [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] | Marketing Assets [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Roll Forward of Goodwill Activity by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Impairment		$ (5,735)		$ (13,981)
Accumulated Goodwill		54,906		47,937
Accumulated impairment		(46,544)		(26,828)
Goodwill Balance		8,362	$ 14,097	14,198
Acquisition measurement period adjustments				116
Sale of MRI assets			(394)
DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisition cost				6,154
VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Acquisition cost			293	800
Detection [Member]
Goodwill [Line Items]
Accumulated Goodwill		699
Fair value allocation		7,663		7,663
Goodwill Balance		8,362	8,362	8,463
Sale of MRI assets			(394)
Detection [Member] | VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Acquisition cost			293	800
Therapy [Member]
Goodwill [Line Items]
Impairment	$ (14,000)	(5,735)		(13,981)
Accumulated Goodwill		6,270
Fair value allocation		13,446		13,446
Accumulated impairment		$ (19,716)
Goodwill Balance			$ 5,735	5,735
Acquisition measurement period adjustments				116
Therapy [Member] | DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisition cost				$ 6,154

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Gross Carrying Amount
Gross Carrying Amount	$ 9,364	$ 10,701
Accumulated Amortization
Accumulated Amortization	7,433	7,518
Total amortizable intangible assets, net	1,931	3,183
Patent and Licenses [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 556	583
Weighted average useful life	5 years
Accumulated Amortization
Accumulated Amortization	$ 503	477
Technology [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 8,257	9,567
Weighted average useful life	10 years
Accumulated Amortization
Accumulated Amortization	$ 6,610	6,754
Customer Relationships [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 292	292
Weighted average useful life	7 years
Accumulated Amortization
Accumulated Amortization	$ 61	28
Tradename [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 259	259
Weighted average useful life	10 years
Accumulated Amortization
Accumulated Amortization	$ 259	$ 259

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Schedule of Expected Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
2,018	$ 417
2,019	379
2,020	305
2,021	228
2,022	299
Thereafter	303
Total amortizable intangible assets, net	$ 1,931	$ 3,183

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Roll Forward of Warranty Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Beginning accrual balance	$ 11	$ 19	$ 14
Warranty provision	49	47	54
Usage	(50)	(55)	(49)
Ending accrual balance	$ 10	$ 11	$ 19

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss available to common shareholders	$ (4,235)	$ (6,933)	$ (2,631)	$ (457)	$ (3,316)	$ (2,675)	$ (1,575)	$ (2,533)	$ (14,256)	$ (10,099)	$ (32,447)
Basic shares used in the calculation of earnings per share									16,343	15,932	15,686
Effect of dilutive securities:
Diluted shares used in the calculation of earnings per share									16,343	15,932	15,686
Basic									$ (0.87)	$ (0.63)	$ (2.07)
Diluted									$ (0.87)	$ (0.63)	$ (2.07)
Stock Options [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements									0	0	0
Restricted Stock [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements									0	0	0

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,880,262	1,936,746	2,088,394
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,465,115	1,425,348	1,571,998
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	415,147	511,398	516,396

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Assets which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets
Total Assets		$ 6,622
Money Market Accounts [Member]
Assets
Total Assets		6,622
Level 1 [Member]
Assets
Total Assets		6,622
Level 1 [Member] | Money Market Accounts [Member]
Assets
Total Assets		$ 6,622
Level 2 [Member]
Assets
Total Assets	$ 8,853
Level 2 [Member] | Money Market Accounts [Member]
Assets
Total Assets	$ 8,853

Acquisitions - Acquisition of V

Acquisitions - Acquisition of VuComp Cancer Detection Portfolio - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Jan. 13, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill		$ 8,362,000	$ 14,097,000		$ 14,198,000
MVu Breast Density [Member]
Business Acquisition [Line Items]
Gain on litigation settlement	$ 249,000
VuComp Cancer Detection Portfolio [Member]
Business Acquisition [Line Items]
Goodwill		$ 293,000		$ 293,000
Goodwill amortization expense useful life		15 years

Acquisitions - Allocation of Pu

Acquisitions - Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) - USD ($)	Jan. 13, 2016	Apr. 29, 2015	Jan. 31, 2016	Apr. 30, 2015	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill					$ 8,362,000	$ 14,198,000	$ 14,097,000
Equipment expected life					3 years
Minimum [Member]
Business Acquisition [Line Items]
Estimated amortizable life					5 years
Maximum [Member]
Business Acquisition [Line Items]
Estimated amortizable life					15 years
MVu Breast Density [Member]
Business Acquisition [Line Items]
Cash	$ 6,000		$ 6,000
Acquisition litigation settlement	249,000
Purchase price	255,000
VuComp Cancer Detection Portfolio [Member]
Business Acquisition [Line Items]
Current assets	84,000
Property and equipment	65,000
Identifiable intangible assets	699,000
Goodwill	293,000				$ 293,000
Current liabilities	(280,000)
Long-term liabilities	(606,000)
Purchase price	$ 255,000
Equipment expected life	3 years
VuComp Cancer Detection Portfolio [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated amortizable life	1 year
VuComp Cancer Detection Portfolio [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated amortizable life	10 years
VuComp M-Vu Breast Density Product [Member]
Business Acquisition [Line Items]
Cash		$ 1,700,000		$ 1,700,000		$ 1,700,000
Developed Technology		900,000
Goodwill		800,000
Purchase price		$ 1,700,000
Estimated amortizable life		8 years 9 months

Acquisitions - Acquisition of42

Acquisitions - Acquisition of VuComp M-Vu Breast Density Product - Additional Information (Detail) - VuComp M-Vu Breast Density Product [Member] - USD ($)	Apr. 29, 2015	Apr. 30, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Business acquisition paid in cash	$ 1,700,000	$ 1,700,000	$ 1,700,000
Estimated amortizable life	8 years 9 months

Sale of MRI Assets - Additional

Sale of MRI Assets - Additional Information (Detail) - USD ($)	Jan. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Allocation of goodwill to asset held for sale			$ 394,000
VersaVue Software and DynaCAD Product and Related Assets [Member] | Asset Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale and transfer of intangible assets			$ 3,200,000
Holdback reserve related to sale and transfer of intangible assets	$ 350,000	$ 350,000
Proceeds from sale and transfer of intangible assets	2,900,000
Allocation of goodwill to asset held for sale		394,000
Gain on sale and transfer of intangible assets	$ 2,500,000	$ 2,508,000

Sale of MRI Assets - Schedule o

Sale of MRI Assets - Schedule of Net Assets Sold (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Assets
Allocated Goodwill		$ 394,000
Total Assets		1,304,000
Liabilities
Total Liabilities		$ 832,000
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | VersaVue Software and DynaCAD Product and Related Assets [Member]
Assets
Accounts Receivable	$ 116,000
Intangible assets	810,000
Allocated Goodwill	394,000
Total Assets	1,320,000
Liabilities
Deferred Revenue	746,000
Total Liabilities	746,000
Net Assets Sold	$ 574,000

Sale of MRI Assets - Schedule45

Sale of MRI Assets - Schedule of Components of Gain on Sale (Detail) - USD ($)	Jan. 30, 2017	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received		$ 2,850,000
Asset Purchase Agreement [Member] | VersaVue Software and DynaCAD Product and Related Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received		2,850,000
Holdback reserve	$ 350,000	350,000
Fair value of transition services		(118,000)
Net Assets sold		(574,000)
Total	$ 2,500,000	$ 2,508,000

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Detail) - USD ($)	6 Months Ended							12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Jul. 30, 2019	Dec. 31, 2017	Aug. 07, 2017
Debt Instrument [Line Items]
Termination fee percentage									2.00%
Line of credit, closing costs					$ 74,000				$ 74,000
Debt instrument repayment term									36 months
Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate					0.50%				0.50%
Minimum [Member]
Debt Instrument [Line Items]
Term loan advances prior to maturity									1.00%
Maximum [Member]
Debt Instrument [Line Items]
Term loan advances prior to maturity									3.00%
Term Loan A [Member]
Debt Instrument [Line Items]
Credit facility, contingent borrowing capacity					$ 3,000,000				$ 3,000,000
Term Loan A [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility										$ 6,000,000
Net revenues					$ 14,000,000	$ 11,500,000	$ 10,250,000
Term Loan A [Member] | Silicon Valley Bank [Member] | Tranche One [Member]
Debt Instrument [Line Items]
Beginning date of repayment									Mar. 1, 2019
Term loan monthly installments									30
Term Loan A [Member] | Silicon Valley Bank [Member] | Tranche Two [Member]
Debt Instrument [Line Items]
Beginning date of repayment									Oct. 1, 2019
Term loan monthly installments									30
Term Loan A [Member] | Minimum [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Adjusted EBITDA requirement									$ (750,000)
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate					1.50%				1.50%
Percentage of outstanding liabilities to bank									125.00%
Revolving Credit Facility [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility										$ 4,000,000
Scenario Forecast [Member] | Term Loan A [Member] | Minimum [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Net revenues								$ 21,500,000
Detection revenue	$ 9,517,000	$ 8,648,000	$ 8,373,000	$ 8,622,000
Adjusted EBITDA	$ 1	$ (1,000,000)	$ (3,750,000)	$ (4,500,000)

Financing Arrangements - Schedu

Financing Arrangements - Schedule of Carrying Value of Term Loan Net of Debt Issuance Costs (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Shares Issued And Outstanding [Line Items]
Less current portion of Term Loan	$ (817)
Notes payable long-term portion	5,119
Term Loan A [Member]
Shares Issued And Outstanding [Line Items]
Principal Amount of Term Loan	6,000
Unamortized closing costs	(64)
Carrying amount of Term Loan	5,936
Carrying amount of Term Loan	5,936
Less current portion of Term Loan	(817)
Notes payable long-term portion	$ 5,119

Financing Arrangements - Summar

Financing Arrangements - Summary of Principal and Interest Payments (Detail) - Term Loan A [Member] $ in Thousands	Dec. 31, 2017USD ($)
Shares Issued And Outstanding [Line Items]
2,018	$ 1,086
2,019	2,183
2,020	2,097
2,021	1,183
Total	$ 6,549

Financing Arrangements - Intere

Financing Arrangements - Interest Expense in Consolidated Income Statement (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Interest Expense, Debt [Abstract]
Cash interest expense	$ 98		$ 163
Non-cash amortization of debt discount			254
Amortization of debt costs	9		13
Amortization of settlement obligations	26	$ 82	146
Interest expense capital lease	1	70	220
Capital lease-fair value amortization	(10)	(89)	(146)
Total interest expense	$ 124	$ 63	$ 650

Accrued Expenses - Accrued Expe

Accrued Expenses - Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued salary and related expenses	$ 1,388	$ 1,878
Accrued accounts payable	2,523	2,269
Accrued professional fees	418	316
Accrued short term settlement costs		474
Other accrued expenses	70	48
Deferred rent	76	3
Accrued Expenses Total	$ 4,475	$ 4,988

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017USD ($)Incentive_Planshares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option | Incentive_Plan	6
Available for future grants	1,037,877
Total unrecognized compensation costs | $	$ 2,000,000
Period of expected recognized over a weighted average	1 year 1 month 6 days
Dividends paid on common stock | $	$ 0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	1 year
Number of restricted stock granted	394,599	345,778	352,666
Performance Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock granted		162,500
Number of shares expected to be earned	190,000
Performance Based Restricted Stock [Member] | Vesting Period One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest	63,200
Performance Based Restricted Stock [Member] | Vesting Period Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest	63,200
Performance Based Restricted Stock [Member] | Vesting Period Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest	63,200
Maximum [Member] | Performance Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares available for granted	108,333
2002 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	100,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of expiration	10 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 years
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
2002 Stock Option Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	5 years
2002 Stock Option Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	6 months
2004 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of options granted	5 months
Period of expiration	10 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 months
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	200,000
2005 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	120,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of options granted	3 years
Period of expiration	5 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 years
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
2007 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	1,050,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Number of share options available for grant	0
Aggregate purchase of Company's common stock, maximum	160,000
Percentage of options granted	100.00%
2012 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	1,600,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Number of share options available for grant	222,377
Aggregate purchase of Company's common stock, maximum	250,000
Percentage of options granted	100.00%
2016 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	1,700,000
Number of share options available for grant		815,500
Aggregate purchase of Company's common stock, maximum	1,000,000
Percentage of options granted		100.00%
Number of share options available for grant | $		$ 100,000
2016 Stock Option Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share options available for grant	1,000,000
2016 Stock Option Plan [Member] | Maximum [Member] | Non Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share options available for grant	50,000

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity for all Stock Option Plans (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning balance	1,425,348	1,571,998	1,417,887
Granted	200,813	127,500	363,239
Exercised	(36,530)	(75,583)	(79,472)
Forfeited	(124,516)	(198,567)	(129,656)
Ending balance	1,465,115	1,425,348	1,571,998
Weighted Average, Beginning Balance	$ 5.05	$ 5.05	$ 4.34
Granted	4.14	5.46	6.58
Exercised	2.18	2.62	4.60
Forfeited	4.71	6.19	7.38
Weighted Average, Ending Balance	$ 5.03	$ 5.05	$ 5.05
Weighted Average Remaining Contractual Term, Outstanding	5 years 3 months 19 days
Exercisable, Number of Shares	1,301,651	1,054,211	1,087,725
Exercisable, Weighted Average Exercise Price	$ 4.95	$ 4.71	$ 4.33
Weighted Average Remaining Contractual Term, Exercisable	5 years

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 3,656	$ 2,307	$ 2,135
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	5	6	14
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	715	329	223
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	1,003	677	659
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 1,933	$ 1,295	$ 1,239

Stockholders' Equity - Options

Stockholders' Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price	$ 4.14	$ 5.46	$ 6.58
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate	1.61%	0.98%	0.97%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average exercise price	$ 4.14	$ 5.46	$ 6.58
Weighted average fair value	$ 1.99	$ 2.66	$ 3.17
Minimum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	64.20%	68.50%	60.50%
Maximum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	72.00%	75.30%	75.20%

Stockholders' Equity - Summar55

Stockholders' Equity - Summary of Intrinsic Values of Options and Closing Market Price (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock options outstanding	$ 449	$ 409	$ 1,910
Stock options exercisable	442	409	1,610
Stock options exercised	$ 79	$ 201	$ 317
Stock price	$ 3.44	$ 3.24	$ 5.17

Stockholders' Equity - Summar56

Stockholders' Equity - Summary of Restricted Stock Activity for All Equity Incentive Plans (Detail) - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning outstanding balance	511,398	516,396	309,317
Granted	394,599	345,778	352,666
Vested	(469,434)	(289,030)	(124,758)
Forfeited	(21,416)	(61,746)	(20,829)
Ending outstanding balance	415,147	511,398	516,396

Stockholders' Equity - Summar57

Stockholders' Equity - Summary of Intrinsic Values of Restricted Stock and Closing Market Price (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding, Stock price	$ 3.44	$ 3.24	$ 5.17
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding, Beginning of period	$ 1,428	$ 1,657	$ 2,670
Number of stock options outstanding, Vested	$ 1,615	$ 936	$ 645
Number of stock options outstanding, Stock price	$ 3.44	$ 3.24	$ 5.17

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current provision (benefit):
Federal	$ 0	$ 0	$ 0
State	(26)	69	95
Current provision (benefit), Total	(26)	69	95
Deferred provision:
Federal	7	6	(65)
State	1	1	(14)
Deferred provision, Total	8	7	(79)
Total	$ (18)	$ 76	$ 16

Income Taxes - Summary of Effec

Income Taxes - Summary of Effective and the Federal Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Federal statutory rate	34.00%	34.00%	34.00%
State income taxes, net of federal benefit	1.40%	2.80%	2.50%
Net state impact of deferred rate change	(0.30%)	0.20%	(0.10%)
Stock compensation expense	(1.90%)	(3.20%)	(0.70%)
Tax amortization on goodwill	(0.10%)	(0.10%)	0.20%
Goodwill impairment	(13.70%)	0.00%	(10.00%)
Other permanent differences	(0.40%)	(0.40%)	(0.10%)
Change in valuation allowance	97.40%	(37.30%)	(26.60%)
Tax credits	1.50%	3.20%	0.90%
Federal Rate Change	(133.50%)	0.00%	0.00%
Accrual to TR	(0.70%)	0.00%	0.00%
Effective income tax	(0.10%)	(0.80%)	0.10%
Xoft Inc [Member]
Income Tax Disclosure [Line Items]
Increase Xoft NOLs under 382 Study	16.20%	0.00%	0.00%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets ( Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Inventory (Section 263A)	$ 287	$ 418
Inventory reserves	305	105
Receivable reserves	27	65
Other accruals	224	434
Deferred revenue	129	215
Accumulated depreciation/amortization	320	477
Stock options	1,901	2,558
Developed technology	2,201	3,594
Tax credits	3,130	3,090
NOL carryforward	31,113	40,865
Net deferred tax assets	39,637	51,821
Valuation allowance	(39,637)	(51,821)
Goodwill tax amortization	(14)	(7)
Deferred tax liability	$ (14)	$ (7)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Income Tax Expense [Line Items]
Federal statutory rate		34.00%	34.00%	34.00%
Goodwill		$ 8,362,000	$ 14,097,000	$ 14,198,000
Net operating loss carryforwards		131,200,000
Net operating losses		(14,168,000)	(9,970,000)	(30,079,000)
Operating losses carryforwards		9,900,000
Net operating losses		2,000,000
Future Income tax liabilities offset With operation loss carryforward		$ 3,100,000
Tax credit carryforward expiration year		2,037
Unrecognized tax benefits		$ 0	0
Interest or penalties related to uncertain tax positions		$ 0	0	$ 0
Company preceding tax years		3 years
Provision to income tax expense for revalue of deferred tax assets and liabilities		$ 19,100,000
Change in valuation allowance		(19,100,000)
Scenario, Plan [Member]
Schedule Of Income Tax Expense [Line Items]
Federal statutory rate	21.00%
Xoft Inc [Member]
Schedule Of Income Tax Expense [Line Items]
Net operating loss carryforwards		54,000,000
Net operating losses		0	0
Operating losses carryforwards		8,500,000
Net operating losses		656,000
Deferred tax assets		0
Asset Acquisition January 2016 [Member]
Schedule Of Income Tax Expense [Line Items]
Goodwill		$ 293,307
Goodwill amortization expense useful life		15 years
Effective income tax rate amortization on goodwill amount		$ 7,434	$ 6,844
Minimum [Member]
Schedule Of Income Tax Expense [Line Items]
Expiring date of net operating loss carryforward		2,019
Maximum [Member]
Schedule Of Income Tax Expense [Line Items]
Expiring date of net operating loss carryforward		2,037

Segment Reporting, Geographic62

Segment Reporting, Geographical Information and Major Customers - Additional Information (Detail)	Dec. 31, 2017USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2017USD ($)SegmentCustomer	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Schedule Of Geographical Information [Line Items]
Number of reporting segments | Segment										2
Total Export Sales		$ 7,902,000	$ 7,000,000	$ 6,409,000	$ 6,791,000	$ 6,928,000	$ 6,003,000	$ 7,369,000	$ 6,038,000	$ 28,102,000	$ 26,338,000	$ 41,554,000
Percentage of export sales to any single country										10.00%
Number of major customers | Customer										1
GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	$ 2,900,000	2,900,000								$ 2,900,000
Oem [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	3,700,000	3,700,000								3,700,000
Two Customers [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	900,000	900,000								900,000
Seven Customers [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	$ 4,600,000	4,600,000								4,600,000
Detection [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales										18,310,000	17,133,000	19,243,000
Sales [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Total revenue										$ 7,100,000	$ 3,900,000	$ 4,100,000
Sales [Member] | Customer Concentration Risk [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables										25.00%	15.00%	10.00%
Sales [Member] | Customer Concentration Risk [Member] | Five Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables										39.00%	30.00%	25.00%
Sales [Member] | Detection [Member] | Customer Concentration Risk [Member] | Five Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables										55.00%	47.00%	53.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	34.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Oem [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	43.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	11.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Seven Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	54.00%
Foreign [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales										$ 3,900,000	$ 2,300,000	$ 2,300,000
Percentage of export sales of total sale										14.00%	9.00%	6.00%
Outstanding receivables	$ 2,100,000	$ 2,100,000				$ 300,000				$ 2,100,000	$ 300,000
Intersegment Eliminations [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales										$ 0

Segment Reporting, Geographic63

Segment Reporting, Geographical Information and Major Customers - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment revenues:
Total revenue	$ 7,902	$ 7,000	$ 6,409	$ 6,791	$ 6,928	$ 6,003	$ 7,369	$ 6,038	$ 28,102	$ 26,338	$ 41,554
Segment gross profit:
Segment gross profit	$ 4,341	$ 4,643	$ 4,503	$ 4,689	$ 4,529	$ 4,101	$ 5,702	$ 4,186	18,176	18,518	29,350
Segment operating income (loss):
Segment operating income (loss)									(8,701)	(2,058)	(21,172)
General, administrative, depreciation and amortization expense									(7,975)	(7,912)	(8,907)
Interest expense									(124)	(63)	(650)
Gain on sale of MRI assets									2,508
Other income									18	10	21
Loss on debt extinguishment											(1,723)
Loss before income tax expense									(14,274)	(10,023)	(32,431)
Detection [Member]
Segment revenues:
Total revenue									18,310	17,133	19,243
Segment gross profit:
Segment gross profit									16,218	15,113	16,019
Segment operating income (loss):
Segment operating income (loss)									6,401	5,694	7,233
Therapy [Member]
Segment revenues:
Total revenue									9,792	9,205	22,311
Segment gross profit:
Segment gross profit									1,958	3,405	13,331
Segment operating income (loss):
Segment operating income (loss)									$ (15,102)	$ (7,752)	$ (28,405)

Segment Reporting, Geographic64

Segment Reporting, Geographical Information and Major Customers - Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	$ 995	$ 1,322	$ 1,580
Amortization	494	983	1,768
Detection [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	172	223	220
Amortization	246	696	532
Therapy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	768	970	1,142
Amortization	$ 222	$ 252	$ 1,213

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended		12 Months Ended
	Jul. 31, 2017USD ($)	Feb. 28, 2010USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)Lease	Dec. 31, 2015USD ($)	Aug. 31, 2017USD ($)
Loss Contingencies [Line Items]
Lease obligations | Lease				3
Annual base rent			$ 47,000			$ 50,000
Operating lease, annual rent, current			764,000
Operating lease, annual rent			1,693,000
Operating lease, annual rent, second year			755,000
Operating lease, annual rent, third year			174,000
Rent expense			899,000	$ 745,000	$ 663,000
Liability recorded on capital leases			$ 39,000			$ 42,000
Equipment expected life			3 years
Purchase obligations to suppliers for future product deliverables			$ 300,000
Employer matching Contribution			500,000
Employer matching Contribution to be paid in next fiscal year			500,000
Minimum annual royalty payment			250,000
Fair value of patent license			$ 100,000
Patent license, Estimated Amortizable Life			4 years
Minimum royalty obligations			$ 400,000
Litigation and settlement obligation, Total			$ 500,000
Nashua [Member]
Loss Contingencies [Line Items]
Term of lease			5 years
Annual base rent			$ 184,518
San Jose California [Member]
Loss Contingencies [Line Items]
Operating lease, annual rent, current			295,140
Operating lease, annual rent			540,588
Operating lease, annual rent, second year			558,120
Operating lease, annual rent, third year			$ 286,368
CADx Medical Systems Inc [Member]
Loss Contingencies [Line Items]
Tax re-assessment received	$ 6,800,000
Reduced tax re-assessment received		$ 703,000

Commitments and Contingencies66

Commitments and Contingencies - Future Minimum Rental Payments (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Leases [Abstract]
2,018	$ 764
2,019	755
2,020	174
Total	$ 1,693

Commitments and Contingencies67

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Capital Leases (Detail) - USD ($)	Dec. 31, 2017	Aug. 31, 2017
Leases [Abstract]
2,018	$ 17,000
2,019	17,000
2,020	13,000
subtotal minimum lease obligation	47,000	$ 50,000
less interest	(8,000)
Total, net	39,000	42,000
Total, net	39,000	$ 42,000
less current portion	(12,000)
long term portion	$ 27,000

Quarterly Financial Data - Quar

Quarterly Financial Data - Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 7,902	$ 7,000	$ 6,409	$ 6,791	$ 6,928	$ 6,003	$ 7,369	$ 6,038	$ 28,102	$ 26,338	$ 41,554
Gross profit	4,341	4,643	4,503	4,689	4,529	4,101	5,702	4,186	18,176	18,518	29,350
Net loss	$ (4,235)	$ (6,933)	$ (2,631)	$ (457)	$ (3,316)	$ (2,675)	$ (1,575)	$ (2,533)	$ (14,256)	$ (10,099)	$ (32,447)
Income (loss) per share	$ (0.26)	$ (0.42)	$ (0.16)	$ (0.03)	$ (0.21)	$ (0.17)	$ (0.10)	$ (0.16)
Weighted average number of shares outstanding	16,501	16,424	16,310	16,135	16,042	15,957	15,904	15,826